


**CUMULATIVE
SUPPLEMENT 2
FEBRUARY 2019**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

39th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2019

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

39th EDITION

**Cumulative Supplement 2
February 2019**

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	viii
1.5 Availability of the Edition	ix
1.6 Report of Counts for the Prescription Drug Product List.....	x
1.7 Cumulative Supplement Legend.....	xi
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

39th EDITION

**CUMULATIVE SUPPLEMENT 2
February 2019**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 39th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the

"@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Cediprof Inc NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Cediprof Inc NDA 021342), Euthyrox (Provell Pharma LLC NDA 021292), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Cediprof Inc NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	CEDIPROF INC	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVOTHYROXINE SODIUM	LUPIN ATLANTIS	0.025MG	AB2	209713	001
EUTHYROX	PROVELL PHARMS	0.025MG	AB2	021292	001
LEVO-T	CEDIPROF INC	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001

LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	CEDIPROF INC	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2018</u>	<u>MAR 2019</u>	<u>JUN 2019</u>	<u>SEP 2019</u>	<u>DEC 2019</u>
DRUG PRODUCTS	20295				
LISTED SINGLE SOURCE	2724 (13.4%)				
MULTISOURCE	17571 (86.6%)				
THERAPEUTICALLY EQUIVALENT	17483 (86.1%)				
NOT THERAPEUTICALLY EQUIVALENT	88 (0.4%)				
EXCEPTIONS ¹	58 (0.3%)				

NEW MOLECULAR ENTITIES APPROVED	25
NUMBER OF APPLICANTS	1133

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
NFTG	New first time generic approval.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.

CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

****Note:**

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABIRATERONE ACETATE

TABLET;ORAL
ABIRATERONE ACETATE

>A>	AB	RISING PHARMS	250MG	A208371	001	Feb 25, 2019	Feb	NEWA
>A>	AB	WOCKHARDT BIO AG	250MG	A208380	001	Feb 27, 2019	Feb	NEWA

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET;ORAL
APADAZ

>D>	+	KEMPHARM	325MG;EQ 4.08MG BASE	N208653	002	Jan 04, 2019	Feb	CAHN
	+		325MG;EQ 4.08MG BASE	N208653	002	Jan 04, 2019	Jan	NEWA
	+		325MG;EQ 4.08MG BASE	N208653	002	Jan 04, 2019	Jan	NEWA
>D>	+		325MG;EQ 6.12MG BASE	N208653	001	Feb 23, 2018	Feb	CAHN
>D>	+		325MG;EQ 8.16MG BASE	N208653	003	Jan 04, 2019	Feb	CAHN
	+		325MG;EQ 8.16MG BASE	N208653	003	Jan 04, 2019	Jan	NEWA
	+		325MG;EQ 8.16MG BASE	N208653	003	Jan 04, 2019	Jan	NEWA
>A>	+	KVK TECH INC	325MG;EQ 4.08MG BASE	N208653	002	Jan 04, 2019	Feb	CAHN
>A>	+		325MG;EQ 6.12MG BASE	N208653	001	Feb 23, 2018	Feb	CAHN
>A>	+		325MG;EQ 8.16MG BASE	N208653	003	Jan 04, 2019	Feb	CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE
@ LANNETT CO INC 120MG/5ML;12MG/5ML

A091238	001	Nov 10, 2011	Jan	DISC
---------	-----	--------------	-----	------

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>A>	AA	WES PHARMA INC	325MG/15ML;7.5MG/15ML	A211023	001	Mar 08, 2019	Feb	NEWA
-----	----	----------------	-----------------------	---------	-----	--------------	-----	------

TABLET;ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@	UPSHER SMITH LABS	325MG;5MG	A206484	001	Mar 24, 2017	Jan	DISC
	@		325MG;7.5MG	A206484	002	Mar 24, 2017	Jan	DISC
	@		325MG;10MG	A206484	003	Mar 24, 2017	Jan	DISC

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL
ACETAZOLAMIDE

>A>	AB	ALEMBIC PHARMS LTD	500MG	A210423	001	Feb 19, 2019	Feb	NEWA
-----	----	--------------------	-------	---------	-----	--------------	-----	------

ACITRETIN

CAPSULE;ORAL
SORIATANE

+	@	STIEFEL LABS INC	17.5MG	N019821	003	Aug 06, 2009	Jan	DISC
+	@		22.5MG	N019821	004	Aug 06, 2009	Jan	DISC

ACYCLOVIR

CREAM;TOPICAL
ACYCLOVIR

AB		PERRIGO UK FINCO	5%	A208702	001	Feb 04, 2019	Jan	NFTG
----	--	------------------	----	---------	-----	--------------	-----	------

ZOVIRAX

>A>	AB	+	!	BAUSCH	5%	N021478	001	Dec 30, 2002	Feb	CAHN
>D>	AB	+	!	VIB	5%	N021478	001	Dec 30, 2002	Feb	CAHN
	AB	+	!		5%	N021478	001	Dec 30, 2002	Jan	CFTG

OINTMENT;TOPICAL
ACYCLOVIR

AB		CIPLA	5%	A211794	001	Jan 18, 2019	Jan	NEWA
----	--	-------	----	---------	-----	--------------	-----	------

>A> AB PERRIGO UK FINCO 5% A205659 001 Feb 20, 2019 Feb NEWA

ZOVIRAX

>A>	AB	+	!	BAUSCH	5%	N018604	001	Mar 29, 1982	Feb	CAHN
>D>	AB	+	!	VALEANT BERMUDA	5%	N018604	001	Mar 29, 1982	Feb	CAHN

ACYCLOVIR SODIUM

INJECTABLE;INJECTION
ACYCLOVIR SODIUM

!		ZYDUS PHARMS USA INC	EQ 500MG BASE/VIAL	A206535	001	Aug 31, 2018	Jan	CHRS
!			EQ 1GM BASE/VIAL	A206535	002	Aug 31, 2018	Jan	CHRS

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL
XERESE

>A>	+	BAUSCH	5%;1%	N022436	001	Jul 31, 2009	Feb CAHN
>D>	+	VALEANT BERMUDA	5%;1%	N022436	001	Jul 31, 2009	Feb CAHN

ALBUTEROL SULFATE

POWDER, METERED; INHALATION
PROAIR DIGIHALER

+ TEVA BRANDED PHARM EQ 0.09MG BASE/INH
PROAIR RESPICLICK
+! TEVA BRANDED PHARM EQ 0.09MG BASE/INH

N205636 002 Dec 21, 2018 Jan NEWA
N205636 001 Mar 31, 2015 Jan CPOT

TABLET; ORAL

ALBUTEROL SULFATE

>A>	AB	APPCO PHARMA LLC	EQ 2MG BASE	A207046	001	Jun 29, 2018	Feb CAHN
>A>	AB		EQ 4MG BASE	A207046	002	Jun 29, 2018	Feb CAHN
>D>	AB	RISING PHARMS	EQ 2MG BASE	A207046	001	Jun 29, 2018	Feb CAHN
>D>	AB		EQ 4MG BASE	A207046	002	Jun 29, 2018	Feb CAHN

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

>A>	AB	UNICHEM LABS LTD	100MG	A211820	001	Mar 12, 2019	Feb NEWA
>A>	AB		300MG	A211820	002	Mar 12, 2019	Feb NEWA

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

AB		RISING PHARMS	EQ 0.5MG BASE	A209180	001	Jan 14, 2019	Jan CAHN
AB			EQ 1MG BASE	A209180	002	Jan 14, 2019	Jan CAHN

ALTRETAMINE

CAPSULE; ORAL

HEXALEN

>D>							
>D>	+	EISAI INC	50MG	N019926	001	Dec 26, 1990	Feb DISC
>A>	+	@	50MG	N019926	001	Dec 26, 1990	Feb DISC

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

>D>	AB	USPHARMA WINDLAS	5MG	A204180	001	Aug 07, 2015	Feb CAHN
>A>	AB	WINDLAS HLTHCARE	5MG	A204180	001	Aug 07, 2015	Feb CAHN

AMINOCAPROIC ACID

TABLET; ORAL

AMICAR

>D>	AB	+	CLOVER PHARMS	1GM	N015197	002	Jun 24, 2004	Feb CHRS
>A>	AB	+		1GM	N015197	002	Jun 24, 2004	Feb CHRS

AMINOCAPROIC ACID

>D>	AB	SUNNY PHARMTECH INC	1GM	A209060	002	Nov 27, 2018	Feb CHRS
>A>	AB	!	1GM	A209060	002	Nov 27, 2018	Feb CHRS

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

>D>	AP	!	HOSPIRA	25MG/ML	A087242	001	Oct 26, 1983	Feb CTEC
>A>		!		25MG/ML	A087242	001	Oct 26, 1983	Feb CTEC
>D>	AP		LUITPOLD	25MG/ML	A087600	001		Feb DISC
>A>		@		25MG/ML	A087600	001		Feb DISC

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

>D>	AB	MYLAN	EQ 2.5MG BASE; 10MG	A077375	001	May 21, 2010	Feb DISC
>A>		@	EQ 2.5MG BASE; 10MG	A077375	001	May 21, 2010	Feb DISC
>D>	AB		EQ 5MG BASE; 10MG	A077375	002	May 21, 2010	Feb DISC
>A>		@	EQ 5MG BASE; 10MG	A077375	002	May 21, 2010	Feb DISC
>D>	AB		EQ 5MG BASE; 20MG	A077375	003	May 21, 2010	Feb DISC
>A>		@	EQ 5MG BASE; 20MG	A077375	003	May 21, 2010	Feb DISC
>D>	AB		EQ 5MG BASE; 40MG	A079047	001	Jul 05, 2011	Feb DISC
>A>		@	EQ 5MG BASE; 40MG	A079047	001	Jul 05, 2011	Feb DISC

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

>D>	AB		EQ 10MG BASE;20MG	A077375	004	May 21, 2010	Feb	DISC
>A>		@	EQ 10MG BASE;20MG	A077375	004	May 21, 2010	Feb	DISC
>D>	AB		EQ 10MG BASE;40MG	A079047	002	Jul 05, 2011	Feb	DISC
>A>		@	EQ 10MG BASE;40MG	A079047	002	Jul 05, 2011	Feb	DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET;ORAL

AUGMENTIN '875'

>D>	AB	+	DR REDDYS LABS INC	875MG;EQ 125MG BASE	N050720	001	Feb 13, 1996	Feb	CAHN
>A>	AB	+	NEOPHARMA	875MG;EQ 125MG BASE	N050720	001	Feb 13, 1996	Feb	CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB			AMERIGEN PHARMS LTD	1.25MG;1.25MG;1.25MG;1.25MG	A205401	001	Jan 22, 2019	Jan	NEWA
AB				2.5MG;2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Jan	NEWA
AB				3.75MG;3.75MG;3.75MG;3.75MG	A205401	003	Jan 22, 2019	Jan	NEWA
AB				5MG;5MG;5MG;5MG	A205401	004	Jan 22, 2019	Jan	NEWA
AB				6.25MG;6.25MG;6.25MG;6.25MG	A205401	005	Jan 22, 2019	Jan	NEWA
AB				7.5MG;7.5MG;7.5MG;7.5MG	A205401	006	Jan 22, 2019	Jan	NEWA

AMPHETAMINE SULFATE

TABLET, ORALLY DISINTEGRATING;ORAL

EVEKEO ODT

+			ARBOR PHARMS LLC	5MG	N209905	001	Jan 30, 2019	Jan	NEWA
+				10MG	N209905	002	Jan 30, 2019	Jan	NEWA
+				15MG	N209905	003	Jan 30, 2019	Jan	NEWA
+				20MG	N209905	004	Jan 30, 2019	Jan	NEWA

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

>D>	AB		FRESENIUS KABI ONCOL	1MG	A090088	001	Jun 28, 2010	Feb	CAHN
>A>	AB		FRESENIUS KABI USA	1MG	A090088	001	Jun 28, 2010	Feb	CAHN

ARIPIPIRAZOLE

SOLUTION;ORAL

ARIPIPIRAZOLE

AA			AUROBINDO PHARMA LTD	1MG/ML	A210479	001	Jan 29, 2019	Jan	NEWA
----	--	--	----------------------	--------	---------	-----	--------------	-----	------

TABLET;ORAL

ARIPIPIRAZOLE

>A>	AB		ALKEM LABS LTD	2MG	A207105	001	Feb 21, 2019	Feb	NEWA
>A>	AB			5MG	A207105	002	Feb 21, 2019	Feb	NEWA
>A>	AB			10MG	A207105	003	Feb 21, 2019	Feb	NEWA
>A>	AB			15MG	A207105	004	Feb 21, 2019	Feb	NEWA
>A>	AB			20MG	A207105	005	Feb 21, 2019	Feb	NEWA
>A>	AB			30MG	A207105	006	Feb 21, 2019	Feb	NEWA

ASENAPINE MALEATE

TABLET;SUBLINGUAL

ASENAPINE MALEATE

>D>	AB		SIGMAPHARM LABS LLC	EQ 5MG BASE	A206107	001	Jul 17, 2018	Feb	DISC
>A>		@		EQ 5MG BASE	A206107	001	Jul 17, 2018	Feb	DISC
>D>	AB			EQ 10MG BASE	A206107	002	Jul 17, 2018	Feb	DISC
>A>		@		EQ 10MG BASE	A206107	002	Jul 17, 2018	Feb	DISC
			SAPHRIS						
>D>	AB	+	FOREST LABS LLC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Feb	CTEC
>A>		+		EQ 5MG BASE	N022117	001	Aug 13, 2009	Feb	CTEC
>D>	AB	+	!	EQ 10MG BASE	N022117	002	Aug 13, 2009	Feb	CTEC
>A>		+	!	EQ 10MG BASE	N022117	002	Aug 13, 2009	Feb	CTEC

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

>A>	AB		ZYDUS PHARMS USA INC	50MG;25MG	A210028	001	Mar 08, 2019	Feb	NEWA
>A>	AB			100MG;25MG	A210028	002	Mar 08, 2019	Feb	NEWA

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

>A>	AB	LUPIN LTD	EQ 10MG BASE	A204991	001	Mar 06, 2019	Feb	NEWA
>A>	AB		EQ 20MG BASE	A204991	002	Mar 06, 2019	Feb	NEWA
>A>	AB		EQ 40MG BASE	A204991	003	Mar 06, 2019	Feb	NEWA
>A>	AB		EQ 80MG BASE	A204991	004	Mar 06, 2019	Feb	NEWA
>A>	AB	MSN LABS PVT LTD	EQ 10MG BASE	A211933	001	Feb 08, 2019	Feb	NEWA
>A>	AB		EQ 20MG BASE	A211933	002	Feb 08, 2019	Feb	NEWA
>A>	AB		EQ 40MG BASE	A211933	003	Feb 08, 2019	Feb	NEWA
>A>	AB		EQ 80MG BASE	A211933	004	Feb 08, 2019	Feb	NEWA

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

ATRACURIUM BESYLATE

>A>	AP	HONG KONG	10MG/ML	A091489	001	Feb 17, 2012	Feb	CAHN
>D>	AP	NANJING KING-FRIEND	10MG/ML	A091489	001	Feb 17, 2012	Feb	CAHN
		ATRACURIUM BESYLATE PRESERVATIVE FREE						
>A>	AP	HONG KONG	10MG/ML	A091488	001	Feb 17, 2012	Feb	CAHN
>D>	AP	NANJING KING-FRIEND	10MG/ML	A091488	001	Feb 17, 2012	Feb	CAHN

AZACITIDINE

POWDER;INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

>A>	AP	LUPIN LTD	100MG/VIAL	A210748	001	Feb 27, 2019	Feb	NEWA
-----	----	-----------	------------	---------	-----	--------------	-----	------

AZITHROMYCIN

TABLET;ORAL

AZITHROMYCIN

>A>	AB	BIONPHARMA INC	EQ 250MG BASE	A210000	001	Feb 26, 2019	Feb	NEWA
>A>	AB		EQ 500MG BASE	A210001	001	Feb 26, 2019	Feb	NEWA

BACLOFEN

TABLET;ORAL

BACLOFEN

AB		EYWA PHARMA	10MG	A211555	001	Feb 01, 2019	Jan	NEWA
AB			20MG	A211555	002	Feb 01, 2019	Jan	NEWA

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

>D>	AB	MYLAN	750MG	A077807	001	Dec 28, 2007	Feb	DISC
>A>		@	750MG	A077807	001	Dec 28, 2007	Feb	DISC

BENZAEPRIIL HYDROCHLORIDE

TABLET;ORAL

BENZAEPRIIL HYDROCHLORIDE

>D>		@ ACTAVIS LABS FL INC	5MG	A076267	001	Feb 11, 2004	Feb	CAHN
>D>		@	10MG	A076267	002	Feb 11, 2004	Feb	CAHN
>D>		@	20MG	A076267	003	Feb 11, 2004	Feb	CAHN
>D>		@	40MG	A076267	004	Feb 11, 2004	Feb	CAHN
>A>		@ HERITAGE PHARMA	5MG	A076267	001	Feb 11, 2004	Feb	CAHN
>A>		@	10MG	A076267	002	Feb 11, 2004	Feb	CAHN
>A>		@	20MG	A076267	003	Feb 11, 2004	Feb	CAHN
>A>		@	40MG	A076267	004	Feb 11, 2004	Feb	CAHN

BENDAMUSTINE HYDROCHLORIDE

POWDER;IV (INFUSION)

TREANDA

>D>	AP	+! CEPHALON	25MG/VIAL	N022249	002	May 01, 2009	Feb	CTEC
>A>		+!	25MG/VIAL	N022249	002	May 01, 2009	Feb	CTEC
>D>	AP	+!	100MG/VIAL	N022249	001	Mar 20, 2008	Feb	CTEC
>A>		+!	100MG/VIAL	N022249	001	Mar 20, 2008	Feb	CTEC

BENZONATATE

CAPSULE;ORAL

BENZONATATE

>A>	AA	ASCENT PHARMS INC	100MG	A211518	001	Feb 22, 2019	Feb	NEWA
>A>	AA		150MG	A211518	002	Feb 22, 2019	Feb	NEWA
>A>	AA		200MG	A211518	003	Feb 22, 2019	Feb	NEWA
>D>	AA	CSPC NBP PHARM CO	100MG	A202765	002	Aug 25, 2017	Feb	CAHN

		CAPSULE;ORAL							
		BENZONATATE							
>D>	AA		200MG	A202765	001	Jul 31, 2015	Feb	CAHN	
>A>	AA	CSPC OUYI	100MG	A202765	002	Aug 25, 2017	Feb	CAHN	
>A>	AA		200MG	A202765	001	Jul 31, 2015	Feb	CAHN	
		<u>BENZTROPINE MESYLATE</u>							
		INJECTABLE;INJECTION							
		BENZTROPINE MESYLATE							
>D>	AP	LUITPOLD	1MG/ML	A091152	001	Mar 29, 2010	Feb	DISC	
>A>		@	1MG/ML	A091152	001	Mar 29, 2010	Feb	DISC	
		<u>BEPOTASTINE BESILATE</u>							
		SOLUTION/DROPS;OPHTHALMIC							
>A>		BEPOTASTINE BESILATE							
>A>	AT	APOTEX INC	1.5%	A206066	001	Mar 05, 2019	Feb	NFTG	
		BEPREVE							
>D>		+!	BAUSCH AND LOMB INC	N022288	001	Sep 08, 2009	Feb	CFTG	
>A>	AT	+!		N022288	001	Sep 08, 2009	Feb	CFTG	
		<u>BICALUTAMIDE</u>							
		TABLET;ORAL							
		BICALUTAMIDE							
>D>	AB	FRESENIUS KABI ONCOL	50MG	A079045	001	May 13, 2010	Feb	CAHN	
>D>	AB		50MG	A079045	001	May 13, 2010	Feb	CAHN	
>A>	AB	FRESENIUS KABI USA	50MG	A079045	001	May 13, 2010	Feb	CAHN	
>A>	AB		50MG	A079045	001	May 13, 2010	Feb	CAHN	
		<u>BISOPROLOL FUMARATE</u>							
		TABLET;ORAL							
		BISOPROLOL FUMARATE							
		@	FRONTIDA BIOPHARM	5MG	A075474	001	Oct 25, 2002	Jan	CAHN
		@		10MG	A075474	002	Oct 25, 2002	Jan	CAHN
		<u>BLEOMYCIN SULFATE</u>							
		INJECTABLE;INJECTION							
		BLEOMYCIN SULFATE							
>A>	AP	CIPLA	EQ 15 UNITS BASE/VIAL	A209439	001	Mar 11, 2019	Feb	NEWA	
		<u>BRIMONIDINE TARTRATE</u>							
		SOLUTION/DROPS;OPHTHALMIC							
		BRIMONIDINE TARTRATE							
>A>	AT	SOMERSET THERAPS LLC	0.2%	A208992	001	Mar 11, 2019	Feb	NEWA	
		<u>BUDESONIDE</u>							
		CAPSULE;ORAL							
		BUDESONIDE							
>A>	AB	APPCO PHARMA LLC	3MG	A207367	001	Apr 07, 2017	Feb	CAHN	
>D>	AB	RISING PHARMS	3MG	A207367	001	Apr 07, 2017	Feb	CAHN	
		<u>BUMETANIDE</u>							
		TABLET;ORAL							
		BUMETANIDE							
>A>	AB	HERITAGE PHARMA	0.5MG	A074225	001	Apr 24, 1995	Feb	CAHN	
>A>	AB		1MG	A074225	002	Apr 24, 1995	Feb	CAHN	
>A>	AB		2MG	A074225	003	Apr 24, 1995	Feb	CAHN	
>D>	AB	IVAX SUB TEVA PHARMS	0.5MG	A074225	001	Apr 24, 1995	Feb	CAHN	
>D>	AB		1MG	A074225	002	Apr 24, 1995	Feb	CAHN	
>D>	AB		2MG	A074225	003	Apr 24, 1995	Feb	CAHN	
		<u>BUPIVACAINE HYDROCHLORIDE</u>							
		INJECTABLE;INJECTION							
		BUPIVACAINE HYDROCHLORIDE							
>A>	AP	NOVOCOL HEALTHCARE	0.5%	A211096	001	Feb 19, 2019	Feb	NEWA	
		<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE</u>							
		FILM;BUCCAL, SUBLINGUAL							
		BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE							
AB		ALVOGEN PINE BROOK	EQ 2MG BASE;EQ 0.5MG BASE	A205954	001	Jan 24, 2019	Jan	NEWA	
AB			EQ 4MG BASE;EQ 1MG BASE	A205954	002	Jan 24, 2019	Jan	NEWA	
AB			EQ 8MG BASE;EQ 2MG BASE	A205954	003	Jan 24, 2019	Jan	NEWA	
AB			EQ 12MG BASE;EQ 3MG BASE	A205954	004	Jan 24, 2019	Jan	NEWA	

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

@ TEVA PHARMS USA EQ 2MG BASE;EQ 0.5MG BASE A091149 001 Sep 08, 2014 Jan DISC
 @ EQ 8MG BASE;EQ 2MG BASE A091149 002 Sep 08, 2014 Jan DISC

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB3 GRAVITI PHARMS 150MG A211020 001 Jan 28, 2019 Jan NEWA
 AB3 300MG A211020 002 Jan 28, 2019 Jan NEWA

BUSULFAN

INJECTABLE;INJECTION

BUSULFAN

>A> AP ACCORD HLTHCARE INC 6MG/ML A210148 001 Feb 22, 2019 Feb NEWA
 AP ATHENEX INC 6MG/ML A205106 001 Sep 21, 2018 Jan CAHN
 >D> AP HOSPIRA INC 6MG/ML A205672 001 Jul 31, 2018 Feb DISC
 >A> @ 6MG/ML A205672 001 Jul 31, 2018 Feb DISC

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

>A> AB SUN PHARM INDS LTD 0.25MCG A204556 001 Feb 21, 2019 Feb NEWA
 >A> AB 0.5MCG A204556 002 Feb 21, 2019 Feb NEWA

CALCIUM ACETATE

TABLET;ORAL

CALCIUM ACETATE

AB CHARTWELL MOLECULAR 667MG A202420 001 Feb 05, 2013 Jan CAHN

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP FRESENIUS KABI USA 20MG/100ML;30MG/100ML;600MG/100ML; A209338 001 Jan 28, 2019 Jan NEWA
 310MG/100ML

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

CARBATROL

AB + SHIRE DEV LLC 100MG N020712 003 Sep 30, 1997 Jan CAHN
 AB + 200MG N020712 001 Sep 30, 1997 Jan CAHN
 AB +! 300MG N020712 002 Sep 30, 1997 Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB ZYDUS PHARMS USA INC 100MG A205571 001 Feb 07, 2019 Jan NEWA
 AB 200MG A205571 002 Feb 07, 2019 Jan NEWA
 AB 400MG A205571 003 Feb 07, 2019 Jan NEWA

CARBOPLATIN

INJECTABLE;IV (INFUSION)

CARBOPLATIN

>A> AP HONG KONG 50MG/5ML (10MG/ML) A077096 001 Jun 14, 2005 Feb CAHN
 >A> AP 150MG/15ML (10MG/ML) A077096 002 Jun 14, 2005 Feb CAHN
 >A> AP 450MG/45ML (10MG/ML) A077096 003 Jun 14, 2005 Feb CAHN
 >A> AP 600MG/60ML (10MG/ML) A077096 004 Jun 03, 2013 Feb CAHN
 >D> AP NANJING KING-FRIEND 50MG/5ML (10MG/ML) A077096 001 Jun 14, 2005 Feb CAHN
 >D> AP 150MG/15ML (10MG/ML) A077096 002 Jun 14, 2005 Feb CAHN
 >D> AP 450MG/45ML (10MG/ML) A077096 003 Jun 14, 2005 Feb CAHN
 >D> AP 600MG/60ML (10MG/ML) A077096 004 Jun 03, 2013 Feb CAHN

CARISOPRODOL

TABLET;ORAL

CARISOPRODOL

>D> AA VINTAGE PHARMS 350MG A040245 001 Sep 08, 1997 Feb DISC
 >A> @ 350MG A040245 001 Sep 08, 1997 Feb DISC

CASPOFUNGIN ACETATE

POWDER;INTRAVENOUS

CASPOFUNGIN ACETATE

@ CIPLA 50MG/VIAL A209489 001 Jul 12, 2018 Jan DISC
 @ 70MG/VIAL A209489 002 Jul 12, 2018 Jan DISC

CEFIXIMEFOR SUSPENSION;ORAL
CEFIXIME

>D>	AB	SANDOZ INC	100MG/5ML	A206144	001	Nov 17, 2017	Feb	DISC
>A>		@	100MG/5ML	A206144	001	Nov 17, 2017	Feb	DISC
>D>	AB		200MG/5ML	A206144	002	Nov 17, 2017	Feb	DISC
>A>		@	200MG/5ML	A206144	002	Nov 17, 2017	Feb	DISC

CEFPODOXIME PROXETILFOR SUSPENSION;ORAL
CEFPODOXIME PROXETIL

		AUROBINDO PHARMA LTD	EQ 50MG BASE/5ML	A065409	001	Jun 08, 2007	Jan	CTEC
		!	EQ 100MG BASE/5ML	A065409	002	Jun 08, 2007	Jan	CHRS
			EQ 100MG BASE/5ML	A065409	002	Jun 08, 2007	Jan	CTEC
		@ SANDOZ	EQ 50MG BASE/5ML	A090031	001	Jan 14, 2009	Jan	DISC
		@	EQ 100MG BASE/5ML	A090031	002	Jan 14, 2009	Jan	DISC

CETIRIZINE HYDROCHLORIDESYRUP;ORAL
CETIRIZINE HYDROCHLORIDE

>D>	AA	ANDA REPOSITORY	5MG/5ML	A090191	001	Nov 12, 2009	Feb	CAHN
>A>	AA	SAPTALIS PHARMS	5MG/5ML	A090191	001	Nov 12, 2009	Feb	CAHN
	AA	TORRENT	5MG/5ML	A078870	001	Apr 27, 2009	Jan	CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDESOLUTION;ORAL
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

		@ TORRENT	4MG/5ML; 5MG/5ML; 60MG/5ML	A206660	001	May 15, 2017	Jan	CAHN
--	--	-----------	----------------------------	---------	-----	--------------	-----	------

CHLORTHALIDONETABLET;ORAL
CHLORTHALIDONE

>A>	AB	INVATECH PHARMA	25MG	A211063	001	Feb 26, 2019	Feb	NEWA
>A>	AB		50MG	A211063	002	Feb 26, 2019	Feb	NEWA

CHROMIC PHOSPHATE P-32INJECTABLE;INJECTION
PHOSPHOCOL P32

		@ CURIUM	5mCi/ML	N017084	001		Jan	CAHN
--	--	----------	---------	---------	-----	--	-----	------

CISATRACURIUM BESYLATEINJECTABLE;INJECTION
CISATRACURIUM BESYLATE

>D>	AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A205873	001	Jun 16, 2017	Feb	DISC
>A>		@	EQ 2MG BASE/ML	A205873	001	Jun 16, 2017	Feb	DISC
			CISATRACURIUM BESYLATE PRESERVATIVE FREE					
>D>	AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A205872	001	Jun 16, 2017	Feb	DISC
>A>		@	EQ 2MG BASE/ML	A205872	001	Jun 16, 2017	Feb	DISC
>D>	AP		EQ 10MG BASE/ML	A205872	002	Jun 16, 2017	Feb	DISC
>A>		@	EQ 10MG BASE/ML	A205872	002	Jun 16, 2017	Feb	DISC
>A>	AP	SOMERSET THERAPS LLC	EQ 2MG BASE/ML	A206791	001	Feb 20, 2019	Feb	NEWA
>A>	AP		EQ 10MG BASE/ML	A206791	002	Feb 20, 2019	Feb	NEWA
			NIMBEX PRESERVATIVE FREE					
>D>		+! ABBVIE	EQ 10MG BASE/ML	N020551	002	Dec 15, 1995	Feb	CTEC
>A>	AP	+!	EQ 10MG BASE/ML	N020551	002	Dec 15, 1995	Feb	CTEC

CLARITHROMYCINTABLET;ORAL
CLARITHROMYCIN

>D>	AB	ALLIED PHARMA INC	250MG	A202710	001	Jun 10, 2013	Feb	CAHN
>D>	AB		500MG	A202710	002	Jun 10, 2013	Feb	CAHN
>A>	AB	STRIDES PHARMA	250MG	A202710	001	Jun 10, 2013	Feb	CAHN
>A>	AB		500MG	A202710	002	Jun 10, 2013	Feb	CAHN

CLINDAMYCIN PHOSPHATESOLUTION;TOPICAL
CLINDAMYCIN PHOSPHATE

AT		ENCUBE ETHICALS	EQ 1% BASE	A209914	001	Jan 28, 2019	Jan	NEWA
----	--	-----------------	------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL
VELTIN

>A>	BX	+!	ALMIRALL	1.2%;0.025%	N050803	001	Jul 16, 2010	Feb CAHN
>D>	BX	+!	AQUA PHARMS LLC	1.2%;0.025%	N050803	001	Jul 16, 2010	Feb CAHN

CLOBAZAM

TABLET;ORAL
CLOBAZAM

AB	MICRO LABS		10MG	A211711	001	Jan 30, 2019	Jan NEWA
AB			20MG	A211711	002	Jan 30, 2019	Jan NEWA

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL
CLOBETASOL PROPIONATE

>A>	AB1		GLENMARK PHARMS LTD	0.05%	A210809	001	Feb 15, 2019	Feb NEWA
-----	-----	--	---------------------	-------	---------	-----	--------------	----------

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

>A>	AB		ALEOR DERMACEUTICALS	0.05%	A211800	001	Mar 04, 2019	Feb NEWA
>D>	AB		AMNEAL PHARMS LLC	0.05%	A210551	001	Aug 21, 2018	Feb DISC
>A>		@		0.05%	A210551	001	Aug 21, 2018	Feb DISC
	AB		TELIGENT PHARMA INC	0.05%	A208589	001	Jan 23, 2019	Jan NEWA

CLOFARABINE

SOLUTION;INTRAVENOUS
CLOFARABINE

>A>	AP		ACCORD HLTHCARE	20MG/20ML (1MG/ML)	A212034	001	Feb 22, 2019	Feb NEWA
>D>	AP		HOSPIRA INC	20MG/20ML (1MG/ML)	A210283	001	Dec 27, 2018	Feb DISC
>A>		@		20MG/20ML (1MG/ML)	A210283	001	Dec 27, 2018	Feb DISC

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION
CLONIDINE HYDROCHLORIDE

>D>	AP		LUITPOLD	1MG/10ML (0.1MG/ML)	A091104	001	Oct 08, 2009	Feb DISC
>A>		@		1MG/10ML (0.1MG/ML)	A091104	001	Oct 08, 2009	Feb DISC
>D>	AP			5MG/10ML (0.5MG/ML)	A091104	002	Oct 08, 2009	Feb DISC
>A>		@		5MG/10ML (0.5MG/ML)	A091104	002	Oct 08, 2009	Feb DISC

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

>A>	AB1		NOVAST LABS	0.1MG	A209675	001	Mar 05, 2019	Feb NEWA
-----	-----	--	-------------	-------	---------	-----	--------------	----------

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

>D>	AB		MYLAN PHARMS INC	EQ 300MG BASE	A077665	002	May 17, 2012	Feb DISC
>A>		@		EQ 300MG BASE	A077665	002	May 17, 2012	Feb DISC

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

@ AUROLIFE PHARMA LLC 3.75MG
@ 7.5MG

A072514	002	May 11, 1990	Jan CMS1
A072514	003	May 11, 1990	Jan CMS1

CLOTRIMAZOLE

SOLUTION;TOPICAL
CLOTRIMAZOLE

>A>	AT		NOVITIUM PHARMA	1%	A209815	001	Feb 14, 2019	Feb NEWA
-----	----	--	-----------------	----	---------	-----	--------------	----------

COLCHICINE

SOLUTION;ORAL

GLOPERBA

+! ROMEG THERAPS LLC 0.6MG/5ML

N210942	001	Jan 30, 2019	Jan NEWA
---------	-----	--------------	----------

TABLET;ORAL

COLCHICINE

>A>	AB		ALKEM LABS LTD	0.6MG	A211250	001	Feb 08, 2019	Feb NEWA
	AB		AMNEAL PHARMS	0.6MG	A204711	001	Sep 28, 2016	Jan NEWA
>A>	AB		ZYDUS PHARMS USA INC	0.6MG	A211519	001	Feb 19, 2019	Feb NEWA
	AB	+!	TAKEDA PHARMS USA	0.6MG	N022352	001	Jul 29, 2009	Jan CTEC

CYCLOBENZAPRINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

>D>	@	APOTEX INC	15MG	A206703	001	Jul 24, 2018	Feb	CMFD
>A>	AB		15MG	A206703	001	Jul 24, 2018	Feb	CMFD
	@		15MG	A206703	001	Jul 24, 2018	Jan	DISC
>D>	@		30MG	A206703	002	Jul 24, 2018	Feb	CMFD
>A>	AB		30MG	A206703	002	Jul 24, 2018	Feb	CMFD
	@		30MG	A206703	002	Jul 24, 2018	Jan	DISC

CYCLOPHOSPHAMIDECAPSULE;ORAL
CYCLOPHOSPHAMIDE

AB		CIPLA	25MG	A211608	001	Jan 18, 2019	Jan	NEWA
AB			50MG	A211608	002	Jan 18, 2019	Jan	NEWA

CYPROHEPTADINE HYDROCHLORIDESYRUP;ORAL
CYPROHEPTADINE HYDROCHLORIDE

AA		TORRENT	2MG/5ML	A204823	001	Dec 27, 2016	Jan	CAHN
>A>	AA	!	HERITAGE PHARMA	A087056	001		Feb	CAHN
>D>	AA	!	IVAX SUB TEVA PHARMS	A087056	001		Feb	CAHN

DACLATASVIR DIHYDROCHLORIDETABLET;ORAL
DAKLINZA

>D>	+	!	BRISTOL-MYERS SQUIBB	EQ 90MG BASE	N206843	003	Apr 13, 2016	Feb	DISC
>A>	+	@		EQ 90MG BASE	N206843	003	Apr 13, 2016	Feb	DISC

DALFAMPRIDINETABLET, EXTENDED RELEASE;ORAL
DALFAMPRIDINE

>A>	AB		MICRO LABS	10MG	A210158	001	Mar 11, 2019	Feb	NEWA
-----	----	--	------------	------	---------	-----	--------------	-----	------

DAPSONEGEL;TOPICAL
ACZONE

>A>	+	!	ALMIRALL	7.5%	N207154	001	Feb 24, 2016	Feb	CAHN
>D>	+	!	AQUA PHARMS LLC	7.5%	N207154	001	Feb 24, 2016	Feb	CAHN

TABLET;ORAL
DAPSONE

>A>	AB		TARO PHARM	25MG	A209430	001	Mar 01, 2019	Feb	NEWA
>A>	AB			100MG	A209430	002	Mar 01, 2019	Feb	NEWA

DEFERIPRONETABLET;ORAL
DEFERIPRONE

>A>	AB		TARO PHARM INDS LTD	500MG	A208800	001	Feb 08, 2019	Feb	NFTG
			FERRIPROX						
>D>	+	!	APOPHARMA INC	500MG	N021825	001	Oct 14, 2011	Feb	CFTG
>A>	AB	+		500MG	N021825	001	Oct 14, 2011	Feb	CFTG

DESMOPRESSIN ACETATEINJECTABLE;INJECTION
DESMOPRESSIN ACETATE

>A>	AP		LUITPOLD	0.004MG/ML	A091374	001	Feb 14, 2019	Feb	NEWA
AB			ABHAI LLC	0.1MG	A210371	001	Jan 28, 2019	Jan	NEWA
AB				0.2MG	A210371	002	Jan 28, 2019	Jan	NEWA

DESONIDEAEROSOL, FOAM;TOPICAL
VERDES0

>A>	+	!	ALMIRALL	0.05%	N021978	001	Sep 19, 2006	Feb	CAHN
>D>	+	!	AQUA PHARMS	0.05%	N021978	001	Sep 19, 2006	Feb	CAHN

OINTMENT; TOPICAL
 DESONIDE

AB	ENCUBE ETHICALS	0.05%	A210998	001	Jan 30, 2019	Jan	NEWA
>A>	TELIGENT PHARMA INC	0.05%	A212002	001	Mar 12, 2019	Feb	NEWA

DESOXIMETASONE

CREAM; TOPICAL
 DESOXIMETASONE

AB	RISING PHARMS	0.05%	A210980	001	Dec 21, 2018	Jan	CAHN
>D>	ZYDUS PHARMS USA INC	0.25%	A205620	001	Sep 28, 2018	Feb	DISC
>A>	@	0.25%	A205620	001	Sep 28, 2018	Feb	DISC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
 DEXAMETHASONE SODIUM PHOSPHATE

>D>	AP	FRESENIUS KABI USA	EQ 4MG PHOSPHATE/ML	A084916	001		Feb	CHRS	
>A>	AP	!	EQ 4MG PHOSPHATE/ML	A084916	001			Feb	CHRS
>D>	AP	!	LUITPOLD	A087440	001	Jul 21, 1982	Feb	DISC	
>A>		@	EQ 4MG PHOSPHATE/ML	A087440	001	Jul 21, 1982	Feb	DISC	

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
 DEXMEDETOMIDINE HYDROCHLORIDE

AP	CIPLA	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204843	001	Jan 18, 2019	Jan	NEWA
----	-------	--	---------	-----	--------------	-----	------

DIAZEPAM

GEL; RECTAL
 DIASTAT

>A>	+	BAUSCH	2.5MG/0.5ML (5MG/ML)	N020648	001	Jul 29, 1997	Feb	CAHN
>A>	+	@	5MG/ML (5MG/ML)	N020648	002	Jul 29, 1997	Feb	CAHN
>A>	+	@	10MG/2ML (5MG/ML)	N020648	003	Jul 29, 1997	Feb	CAHN
>A>	+	@	15MG/3ML (5MG/ML)	N020648	004	Jul 29, 1997	Feb	CAHN
>A>	+	@	20MG/4ML (5MG/ML)	N020648	005	Jul 29, 1997	Feb	CAHN
>D>	+	VALEANT PHARMS NORTH	2.5MG/0.5ML (5MG/ML)	N020648	001	Jul 29, 1997	Feb	CAHN
>D>	+	@	5MG/ML (5MG/ML)	N020648	002	Jul 29, 1997	Feb	CAHN
>D>	+	@	10MG/2ML (5MG/ML)	N020648	003	Jul 29, 1997	Feb	CAHN
>D>	+	@	15MG/3ML (5MG/ML)	N020648	004	Jul 29, 1997	Feb	CAHN
>D>	+	@	20MG/4ML (5MG/ML)	N020648	005	Jul 29, 1997	Feb	CAHN
			DIASTAT ACUDIAL					
>A>	+	BAUSCH	10MG/2ML (5MG/ML)	N020648	007	Sep 15, 2005	Feb	CAHN
>A>	+	!	20MG/4ML (5MG/ML)	N020648	006	Sep 15, 2005	Feb	CAHN
>D>	+	VALEANT PHARMS NORTH	10MG/2ML (5MG/ML)	N020648	007	Sep 15, 2005	Feb	CAHN
>D>	+	!	20MG/4ML (5MG/ML)	N020648	006	Sep 15, 2005	Feb	CAHN

DICLOFENAC

CAPSULE; ORAL
 ZORVOLEX

>A>	+	EGALET	18MG	N204592	001	Oct 18, 2013	Feb	CAHN
>A>	+	!	35MG	N204592	002	Oct 18, 2013	Feb	CAHN
>D>	+	IROKO PHARMS LLC	18MG	N204592	001	Oct 18, 2013	Feb	CAHN
>D>	+	!	35MG	N204592	002	Oct 18, 2013	Feb	CAHN

DICLOFENAC EPOLAMINE

SYSTEM; TOPICAL
 LICART

>D>	+	IBSA INST BIO	1.3%	N206976	001	Dec 19, 2018	Feb	DISC
>A>	+	@	1.3%	N206976	001	Dec 19, 2018	Feb	DISC

DICYCLOMINE HYDROCHLORIDE

INJECTABLE; INJECTION
 DICYCLOMINE HYDROCHLORIDE

>D>	AP	APC PHARMS LLC	10MG/ML	A210979	001	Jul 02, 2018	Feb	DISC
>A>		@	10MG/ML	A210979	001	Jul 02, 2018	Feb	DISC
	AP	CUSTOPHARM INC	10MG/ML	A210788	001	Feb 11, 2019	Jan	NEWA
	AP	FRESENIUS KABI USA	10MG/ML	A210257	001	Jan 25, 2019	Jan	NEWA
	AP	NEXUS PHARMS	10MG/ML	A206468	001	Feb 01, 2019	Jan	NEWA
>D>	AP	RENAISSANCE SSA LLC	10MG/ML	A207076	001	Nov 02, 2018	Feb	CAHN
>A>	AP	SLATE	10MG/ML	A207076	001	Nov 02, 2018	Feb	CAHN

DIHYDROERGOTAMINE MESYLATE

SPRAY, METERED;NASAL
MIGRANAL

+! VALEANT 0.5MG/SPRAY N020148 001 Dec 08, 1997 Jan CPOT

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
CARDIZEM CD

>A> AB3 + BAUSCH 120MG N020062 001 Aug 10, 1992 Feb CAHN
>A> AB3 + 180MG N020062 002 Dec 27, 1991 Feb CAHN
>A> AB3 + 240MG N020062 003 Dec 27, 1991 Feb CAHN
>A> AB3 + 300MG N020062 004 Dec 27, 1991 Feb CAHN
>A> AB3 +! 360MG N020062 005 Aug 24, 1999 Feb CAHN
>D> AB3 + VALEANT INTL 120MG N020062 001 Aug 10, 1992 Feb CAHN
>D> AB3 + 180MG N020062 002 Dec 27, 1991 Feb CAHN
>D> AB3 + 240MG N020062 003 Dec 27, 1991 Feb CAHN
>D> AB3 + 300MG N020062 004 Dec 27, 1991 Feb CAHN
>D> AB3 +! 360MG N020062 005 Aug 24, 1999 Feb CAHN

TIAZAC

>A> AB4 + BAUSCH 120MG N020401 001 Sep 11, 1995 Feb CAHN
>A> AB4 + 180MG N020401 002 Sep 11, 1995 Feb CAHN
>A> AB4 + 240MG N020401 003 Sep 11, 1995 Feb CAHN
>A> AB4 + 300MG N020401 004 Sep 11, 1995 Feb CAHN
>A> AB4 + 360MG N020401 005 Sep 11, 1995 Feb CAHN
>A> AB4 +! 420MG N020401 006 Oct 16, 1998 Feb CAHN
>D> AB4 + VALEANT PHARMS NORTH 120MG N020401 001 Sep 11, 1995 Feb CAHN
>D> AB4 + 180MG N020401 002 Sep 11, 1995 Feb CAHN
>D> AB4 + 240MG N020401 003 Sep 11, 1995 Feb CAHN
>D> AB4 + 300MG N020401 004 Sep 11, 1995 Feb CAHN
>D> AB4 + 360MG N020401 005 Sep 11, 1995 Feb CAHN
>D> AB4 +! 420MG N020401 006 Oct 16, 1998 Feb CAHN

DOCETAXEL

SOLUTION;INTRAVENOUS
DOCETAXEL

AP SUN PHARMA GLOBAL 20MG/ML (20MG/ML) N022534 003 Jan 08, 2019 Jan NEWA
AP 80MG/4ML (20MG/ML) N022534 004 Jan 08, 2019 Jan NEWA
AP 160MG/8ML (20MG/ML) N022534 005 Jan 08, 2019 Jan NEWA

DOFETILIDE

CAPSULE;ORAL
DOFETILDE

AB AUROBINDO PHARMA LTD 0.125MG A210740 001 Jan 22, 2019 Jan NEWA
AB 0.25MG A210740 002 Jan 22, 2019 Jan NEWA
AB 0.5MG A210740 003 Jan 22, 2019 Jan NEWA

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION
DOPAMINE HYDROCHLORIDE

>D> AP ! LUITPOLD 40MG/ML A070799 001 Feb 11, 1987 Feb DISC
>A> @ 40MG/ML A070799 001 Feb 11, 1987 Feb DISC
>D> AP ! 80MG/ML A070820 001 Feb 11, 1987 Feb DISC
>A> @ 80MG/ML A070820 001 Feb 11, 1987 Feb DISC

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE

AT FDC LTD EQ 2% BASE A205294 001 Jan 24, 2019 Jan NEWA

DOXEPIIN HYDROCHLORIDE

CAPSULE;ORAL
DOXEPIIN HYDROCHLORIDE

AB PAR PHARM EQ 10MG BASE A071697 001 Nov 09, 1987 Jan CMFD
AB EQ 25MG BASE A071437 001 Nov 09, 1987 Jan CMFD
AB EQ 75MG BASE A071608 001 Nov 09, 1987 Jan CMFD

TABLET;ORAL
SILENOR

>A> + PERNIX EQ 3MG BASE N022036 001 Mar 17, 2010 Feb CAHN
>A> +! EQ 6MG BASE N022036 002 Mar 17, 2010 Feb CAHN
>D> + PERNIX THERAPS LLC EQ 3MG BASE N022036 001 Mar 17, 2010 Feb CAHN
>D> +! EQ 6MG BASE N022036 002 Mar 17, 2010 Feb CAHN

DOXYCYCLINECAPSULE;ORAL
MONODOX

>A>	AB	+	ALMIRALL	EQ 50MG BASE	N050641	002	Feb 10, 1992	Feb	CAHN
>A>	AB	+		EQ 75MG BASE	N050641	003	Oct 18, 2006	Feb	CAHN
>A>	AB	+	!	EQ 100MG BASE	N050641	001	Dec 29, 1989	Feb	CAHN
>D>	AB	+	AQUA PHARMS	EQ 50MG BASE	N050641	002	Feb 10, 1992	Feb	CAHN
>D>	AB	+		EQ 75MG BASE	N050641	003	Oct 18, 2006	Feb	CAHN
>D>	AB	+	!	EQ 100MG BASE	N050641	001	Dec 29, 1989	Feb	CAHN

DOXYCYCLINE HYCLATECAPSULE;ORAL
ACTICLATE CAP

>A>		+	@	ALMIRALL	EQ 75MG BASE	N208253	001	Apr 26, 2016	Feb	CAHN
>D>		+	@	AQUA PHARMS	EQ 75MG BASE	N208253	001	Apr 26, 2016	Feb	CAHN

TABLET;ORAL
ACTICLATE

>A>	AB	+	ALMIRALL	EQ 75MG BASE	N205931	001	Jul 25, 2014	Feb	CAHN
>A>	AB	+	!	EQ 150MG BASE	N205931	002	Jul 25, 2014	Feb	CAHN
>D>	AB	+	AQUA PHARMS LLC	EQ 75MG BASE	N205931	001	Jul 25, 2014	Feb	CAHN
>D>	AB	+	!	EQ 150MG BASE	N205931	002	Jul 25, 2014	Feb	CAHN

DOXYCYCLINE HYCLATE

>A>	AB		CADILA	EQ 100MG BASE	A207773	001	Oct 30, 2017	Feb	CAHN
>D>	AB		ZYDUS PHARMS USA INC	EQ 100MG BASE	A207773	001	Oct 30, 2017	Feb	CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL-28

>A>			KEMEYA						
>A>	AB		SUN PHARM INDS LTD	3MG;0.03MG	A202138	001	Mar 13, 2019	Feb	NEWA

DULOXETINE HYDROCHLORIDECAPSULE, DELAYED REL PELLETS;ORAL
DULOXETINE HYDROCHLORIDE

>A>	AB		AJANTA PHARMA LTD	EQ 40MG BASE	A208706	004	Mar 11, 2019	Feb	NEWA
-----	----	--	-------------------	--------------	---------	-----	--------------	-----	------

DUTASTERIDECAPSULE;ORAL
DUTASTERIDE

>A>	AB		CADILA	0.5MG	A204373	001	Oct 04, 2017	Feb	CAHN
>D>	AB		RISING PHARMS	0.5MG	A202530	001	Nov 20, 2015	Feb	DISC
>A>			@	0.5MG	A202530	001	Nov 20, 2015	Feb	DISC
>D>	AB		ZYDUS PHARMS USA INC	0.5MG	A204373	001	Oct 04, 2017	Feb	CAHN

EFAVIRENZTABLET;ORAL
EFAVIRENZ

>D>	AB		AUROBINDO PHARMA LTD	600MG	A077673	001	Sep 21, 2018	Feb	DISC
>A>			@	600MG	A077673	001	Sep 21, 2018	Feb	DISC

EFINACONAZOLESOLUTION;TOPICAL
JUBLIA

>A>		+	!	BAUSCH	10%	N203567	001	Jun 06, 2014	Feb	CAHN
>D>		+	!	VALEANT PHARMS INTL	10%	N203567	001	Jun 06, 2014	Feb	CAHN

ELTROMBOPAG OLAMINETABLET;ORAL
PROMACTA

>D>		+	!	NOVARTIS PHARMS CORP	EQ 100MG ACID	N022291	005	Nov 16, 2012	Feb	DISC
>A>		+	@		EQ 100MG ACID	N022291	005	Nov 16, 2012	Feb	DISC

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

>D>	AB		AMNEAL PHARMS CO	100MG;150MG	A209721	001	Aug 22, 2018	Feb	DISC
>A>			@	100MG;150MG	A209721	001	Aug 22, 2018	Feb	DISC
>D>	AB			133MG;200MG	A209721	002	Aug 22, 2018	Feb	DISC
>A>			@	133MG;200MG	A209721	002	Aug 22, 2018	Feb	DISC
>D>	AB			167MG;250MG	A209721	003	Aug 22, 2018	Feb	DISC
>A>			@	167MG;250MG	A209721	003	Aug 22, 2018	Feb	DISC
>D>	AB			200MG;300MG	A209721	004	Aug 22, 2018	Feb	DISC

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

>A>	@		200MG;300MG	A209721	004	Aug 22, 2018	Feb DISC	
		TRUVADA						
>D>	AB	+	GILEAD	100MG;150MG	N021752	002	Mar 10, 2016	Feb CTEC
>A>				100MG;150MG	N021752	002	Mar 10, 2016	Feb CTEC
>D>	AB	+		133MG;200MG	N021752	003	Mar 10, 2016	Feb CTEC
>A>				133MG;200MG	N021752	003	Mar 10, 2016	Feb CTEC
>D>	AB	+		167MG;250MG	N021752	004	Mar 10, 2016	Feb CTEC
>A>				167MG;250MG	N021752	004	Mar 10, 2016	Feb CTEC

ENALAPRIL MALEATE

TABLET;ORAL

ENALAPRIL MALEATE

>A>	@	BEXIMCO PHARMS USA	2.5MG	A075621	001	Aug 22, 2000	Feb CAHN
>A>	@		5MG	A075621	002	Aug 22, 2000	Feb CAHN
>A>	@		10MG	A075621	003	Aug 22, 2000	Feb CAHN
>A>	@		20MG	A075621	004	Aug 22, 2000	Feb CAHN
>A>	AB	HERITAGE PHARMA	2.5MG	A075479	001	Aug 22, 2000	Feb CAHN
>A>	AB		5MG	A075479	002	Aug 22, 2000	Feb CAHN
>A>	AB		10MG	A075479	003	Aug 22, 2000	Feb CAHN
>A>	AB		20MG	A075479	004	Aug 22, 2000	Feb CAHN
>D>	AB	MYLAN	10MG	A075480	003	Aug 22, 2000	Feb DISC
>A>	@		10MG	A075480	003	Aug 22, 2000	Feb DISC
>D>	@	SANDOZ INC	2.5MG	A075621	001	Aug 22, 2000	Feb CAHN
>D>	@		5MG	A075621	002	Aug 22, 2000	Feb CAHN
>D>	@		10MG	A075621	003	Aug 22, 2000	Feb CAHN
>D>	@		20MG	A075621	004	Aug 22, 2000	Feb CAHN
>D>	AB	TEVA	2.5MG	A075479	001	Aug 22, 2000	Feb CAHN
>D>	AB		5MG	A075479	002	Aug 22, 2000	Feb CAHN
>D>	AB		10MG	A075479	003	Aug 22, 2000	Feb CAHN
>D>	AB		20MG	A075479	004	Aug 22, 2000	Feb CAHN

EPINEPHRINE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

ADRENALIN

AP	+	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Jan CDFR
	+		EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Jan CDFR

EPTIFIBATIDE

INJECTABLE;INJECTION

EPTIFIBATIDE

AP		BAXTER HLTHCARE CORP	2MG/ML	A208554	001	Nov 23, 2018	Jan CAHN
AP			75MG/100ML	A208554	002	Nov 23, 2018	Jan CAHN
AP		HAINAN POLY PHARM	2MG/ML	A209864	001	Jan 25, 2019	Jan NEWA
AP			75MG/100ML	A209864	002	Jan 25, 2019	Jan NEWA
>A>	AP	USV	2MG/ML	A204362	001	Mar 11, 2019	Feb NEWA

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

>D>	@	MYLAN PHARMS INC	EQ 25MG BASE	A091002	001	Jun 11, 2014	Feb CMFD
>A>	AB		EQ 25MG BASE	A091002	001	Jun 11, 2014	Feb CMFD
>D>	@		EQ 100MG BASE	A091002	002	Jun 11, 2014	Feb CMFD
>A>	AB		EQ 100MG BASE	A091002	002	Jun 11, 2014	Feb CMFD
>D>	@		EQ 150MG BASE	A091002	003	Jun 11, 2014	Feb CMFD
>A>	AB		EQ 150MG BASE	A091002	003	Jun 11, 2014	Feb CMFD
		TARCEVA					
>D>	+	OSI PHARMS	EQ 25MG BASE	N021743	001	Nov 18, 2004	Feb CTEC
>A>	AB		EQ 25MG BASE	N021743	001	Nov 18, 2004	Feb CTEC
>D>	+		EQ 100MG BASE	N021743	002	Nov 18, 2004	Feb CTEC
>A>	AB		EQ 100MG BASE	N021743	002	Nov 18, 2004	Feb CTEC
>D>	+		EQ 150MG BASE	N021743	003	Nov 18, 2004	Feb CTEC
>A>	AB		EQ 150MG BASE	N021743	003	Nov 18, 2004	Feb CTEC

ERYTHROMYCIN

SOLUTION;TOPICAL

ERYTHRA-DERM

>D>	@	ANDA REPOSITORY	2%	A062687	001	Feb 05, 1988	Feb CAHN
>A>	@	SAPTALIS PHARMS	2%	A062687	001	Feb 05, 1988	Feb CAHN

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL
ESTRADIOL

AB1	AMNEAL PHARMS LLC	0.025MG/24HR	A211293	001	Feb 04, 2019	Jan NEWA
AB1		0.0375MG/24HR	A211293	002	Feb 04, 2019	Jan NEWA
AB1		0.05MG/24HR	A211293	003	Feb 04, 2019	Jan NEWA
AB1		0.075MG/24HR	A211293	004	Feb 04, 2019	Jan NEWA
AB1		0.1MG/24HR	A211293	005	Feb 04, 2019	Jan NEWA

GEL;TRANSDERMAL
DIVIGEL

+!	VERTICAL PHARMS LLC	0.1%	N022038	001	Jun 04, 2007	Jan CHRS
----	---------------------	------	---------	-----	--------------	----------

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET;ORAL
CENESTIN

>A>	+ @ ASPEN	0.3MG	N020992	001	Jun 21, 2002	Feb CAHN
>A>	+ @	0.45MG	N020992	005	Feb 05, 2004	Feb CAHN
>A>	+ @	0.625MG	N020992	002	Mar 24, 1999	Feb CAHN
>A>	+ @	0.9MG	N020992	003	Mar 24, 1999	Feb CAHN
>A>	+ @	1.25MG	N020992	004	Mar 13, 2000	Feb CAHN
>D>	+ @ TEVA BRANDED PHARM	0.3MG	N020992	001	Jun 21, 2002	Feb CAHN
>D>	+ @	0.45MG	N020992	005	Feb 05, 2004	Feb CAHN
>D>	+ @	0.625MG	N020992	002	Mar 24, 1999	Feb CAHN
>D>	+ @	0.9MG	N020992	003	Mar 24, 1999	Feb CAHN
>D>	+ @	1.25MG	N020992	004	Mar 13, 2000	Feb CAHN

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET;ORAL
ENJUVIA

>A>	@ ASPEN	0.3MG	N021443	001	Dec 20, 2004	Feb CAHN
>A>	@	0.45MG	N021443	002	Dec 20, 2004	Feb CAHN
>A>	@	0.625MG	N021443	003	May 10, 2004	Feb CAHN
>A>	@	0.9MG	N021443	005	Apr 27, 2007	Feb CAHN
>A>	@	1.25MG	N021443	004	May 10, 2004	Feb CAHN
>D>	@ TEVA BRANDED PHARM	0.3MG	N021443	001	Dec 20, 2004	Feb CAHN
>D>	@	0.45MG	N021443	002	Dec 20, 2004	Feb CAHN
>D>	@	0.625MG	N021443	003	May 10, 2004	Feb CAHN
>D>	@	0.9MG	N021443	005	Apr 27, 2007	Feb CAHN
>D>	@	1.25MG	N021443	004	May 10, 2004	Feb CAHN

ETHACRYNATE SODIUM

INJECTABLE;INJECTION
EDECIN

AP	+!	VALEANT PHARMS INTL	EQ 50MG BASE/VIAL	N016093	001	Jan CAHN
----	----	---------------------	-------------------	---------	-----	----------

ETHACRYNIC ACID

TABLET;ORAL
EDECIN

AB	+!	VALEANT PHARMS INTL	25MG	N016092	001	Jan CAHN
	@		50MG	N016092	002	Jan CAHN

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-28
LO-MALMOREDE

AB		NOVAST LABS	0.035MG;1MG	A209548	001	Feb 11, 2019	Jan NEWA
----	--	-------------	-------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL
SYLEVIA

AB		SUN PHARM INDS LTD	0.03MG;0.15MG	A202988	001	Feb 06, 2019	Jan NEWA
----	--	--------------------	---------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL-21
HAILEY 1.5/30

AB		GLENMARK PHARMS	0.03MG;1.5MG	A209297	001	Jun 05, 2018	Jan CDFR
		LOESTRIN 21 1.5/30					
AB	+	APIL	0.03MG;1.5MG	N017875	001		Jan CRLD
		LOESTRIN 21 1/20					
AB	+	APIL	0.02MG;1MG	N017876	001		Jan CRLD

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

@ MYLAN LABS LTD 0.025MG,0.025MG,0.025MG;0.18MG,0.2 15MG,0.25MG A202132 001 Sep 09, 2015 Jan DISC

>D> ETHINYL ESTRADIOL; SEGESTERONE ACETATE

>D> RING;VAGINAL

>D> ANNOVERA

>D> +! THERAPEUTICSMD INC 0.013MG/24HR;0.15MG/24HR N209627 001 Aug 10, 2018 Feb DISC

>A> + @ 0.013MG/24HR;0.15MG/24HR N209627 001 Aug 10, 2018 Feb DISC

ETHOSUXIMIDE

CAPSULE;ORAL

ETHOSUXIMIDE

>A> AB STRIDES PHARMA 250MG A211928 001 Feb 19, 2019 Feb NEWA

ETOMIDATE

INJECTABLE;INJECTION

ETOMIDATE

>D> AP LUITPOLD 2MG/ML A078867 001 Dec 22, 2009 Feb DISC

>A> @ 2MG/ML A078867 001 Dec 22, 2009 Feb DISC

EXEMESTANE

TABLET;ORAL

EXEMESTANE

>A> AB BRECKENRIDGE PHARM 25MG A211031 001 Feb 21, 2019 Feb NEWA

FENOFIBRATE

CAPSULE;ORAL

FENOFIBRATE (MICRONIZED)

AB AUSTARPHARMA 67MG A207805 001 Nov 16, 2017 Jan CAHN

AB 134MG A207805 002 Nov 16, 2017 Jan CAHN

AB 200MG A207805 003 Nov 16, 2017 Jan CAHN

TABLET;ORAL

FENOFIBRATE

AB AUSTARPHARMA 54MG A207803 001 Dec 19, 2017 Jan CAHN

AB 160MG A207803 002 Dec 19, 2017 Jan CAHN

>D> AB GRAVITI PHARMS 54MG A210606 001 Aug 17, 2018 Feb DISC

>A> @ 54MG A210606 001 Aug 17, 2018 Feb DISC

>D> AB 160MG A210606 002 Aug 17, 2018 Feb DISC

>A> @ 160MG A210606 002 Aug 17, 2018 Feb DISC

AB ORIT LABS LLC 54MG A209660 001 Feb 11, 2019 Jan NEWA

AB 160MG A209660 002 Feb 11, 2019 Jan NEWA

FENOFIBRIC ACID

TABLET;ORAL

FIBRICOR

>D> + ARALEZ PHARMS INC 35MG N022418 001 Aug 14, 2009 Feb CAHN

>D> +! 105MG N022418 002 Aug 14, 2009 Feb CAHN

>A> + ATHENA 35MG N022418 001 Aug 14, 2009 Feb CAHN

>A> +! 105MG N022418 002 Aug 14, 2009 Feb CAHN

FLUCYTOSINE

CAPSULE;ORAL

ANCOBON

>A> AB + BAUSCH 250MG N017001 001 Feb CAHN

>A> AB +! 500MG N017001 002 Feb CAHN

>D> AB + VALEANT 250MG N017001 001 Feb CAHN

>D> AB +! 500MG N017001 002 Feb CAHN

FLUOCINOLONE ACETONIDE

SOLUTION;TOPICAL

FLUOCINOLONE ACETONIDE

AT ENCUBE ETHICALS 0.01% A209913 001 Feb 13, 2019 Jan NEWA

>D> AT GAVIS PHARMS LLC 0.01% A206422 001 Sep 02, 2015 Feb CAHN

AT GLASSHOUSE PHARMS 0.01% A209596 001 Dec 26, 2017 Jan CMFD

>A> AT LUPIN 0.01% A206422 001 Sep 02, 2015 Feb CAHN

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE

>D>	AB1	AMNEAL PHARMS LLC	0.05%	A210554	001	Aug 21, 2018	Feb DISC
>A>		@	0.05%	A210554	001	Aug 21, 2018	Feb DISC

FLUOROMETHOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC
FLAREX

>A>	+	!	EYEVANCE	0.1%	N019079	001	Feb 11, 1986	Feb CAHN
>D>	+	!	NOVARTIS PHARMS CORP	0.1%	N019079	001	Feb 11, 1986	Feb CAHN

FLUOROURACIL

CREAM; TOPICAL
FLUOROPLEX

>A>	+	!	ALMIRALL	1%	N016988	001		Feb CAHN
>D>	+	!	AQUA PHARMS	1%	N016988	001		Feb CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL
FLUOXETINE HYDROCHLORIDE

>A>	@	BEXIMCO PHARMS USA	EQ 10MG BASE	A075807	001	Jan 29, 2002	Feb CAHN
>A>	@		EQ 20MG BASE	A075807	002	Jan 29, 2002	Feb CAHN
>D>	@	SANDOZ	EQ 10MG BASE	A075807	001	Jan 29, 2002	Feb CAHN
>D>	@		EQ 20MG BASE	A075807	002	Jan 29, 2002	Feb CAHN

TABLET; ORAL
FLUOXETINE HYDROCHLORIDE

AB		APPCO PHARMA LLC	EQ 10MG BASE	A211696	001	Jan 30, 2019	Jan NEWA
AB			EQ 20MG BASE	A211696	002	Jan 30, 2019	Jan NEWA
AB		DR REDDYS LABS LTD	EQ 60MG BASE	A211721	001	Jan 25, 2019	Jan NEWA
>A>	AB	LUPIN LTD	EQ 60MG BASE	A211632	001	Feb 08, 2019	Feb NEWA

FLURANDRENOLIDE

CREAM; TOPICAL
CORDRAN SP

>A>	+	!	ALMIRALL	0.025%	N012806	003		Feb CAHN
>A>	AT	+	!	0.05%	N012806	002		Feb CAHN
>D>	+	!	AQUA PHARMS	0.025%	N012806	003		Feb CAHN
>D>	AT	+	!	0.05%	N012806	002		Feb CAHN

LOTION; TOPICAL
CORDRAN

>A>	AT	+	!	ALMIRALL	0.05%	N013790	001	Feb CAHN
>D>	AT	+	!	AQUA PHARMS	0.05%	N013790	001	Feb CAHN

OINTMENT; TOPICAL
CORDRAN

>A>	+	@	ALMIRALL	0.025%	N012806	004		Feb CAHN
>A>	AT	+	!	0.05%	N012806	001		Feb CAHN
>D>	+	@	AQUA PHARMS	0.025%	N012806	004		Feb CAHN
>D>	AT	+	!	0.05%	N012806	001		Feb CAHN

TAPE; TOPICAL
CORDRAN

>A>	+	!	ALMIRALL	0.004MG/SQ CM	N016455	001		Feb CAHN
>D>	+	!	AQUA PHARMS LLC	0.004MG/SQ CM	N016455	001		Feb CAHN

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER; INHALATION
ADV AIR DISKUS 100/50

AB	+	!	GLAXO GRP LTD	0.1MG/INH;EQ 0.05MG BASE/INH	N021077	001	Aug 24, 2000	Jan CFTG
----	---	---	---------------	------------------------------	---------	-----	--------------	----------

AB	+	!	GLAXO GRP LTD	0.25MG/INH;EQ 0.05MG BASE/INH	N021077	002	Aug 24, 2000	Jan CFTG
----	---	---	---------------	-------------------------------	---------	-----	--------------	----------

AB	+	!	GLAXO GRP LTD	0.5MG/INH;EQ 0.05MG BASE/INH	N021077	003	Aug 24, 2000	Jan CFTG
----	---	---	---------------	------------------------------	---------	-----	--------------	----------

WIXELA INHUB
MYLAN PHARMS INC

AB				0.1MG/INH;EQ 0.05MG BASE/INH	A208891	001	Jan 30, 2019	Jan NFTG
AB				0.25MG/INH;EQ 0.05MG BASE/INH	A208891	002	Jan 30, 2019	Jan NFTG
AB				0.5MG/INH;EQ 0.05MG BASE/INH	A208891	003	Jan 30, 2019	Jan NFTG

FOLIC ACID

TABLET;ORAL
FOLIC ACID

>A> AA INVATECH PHARMA 1MG A211064 001 Mar 08, 2019 Feb NEWA

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION
FOSPHENYTOIN SODIUM

>D> AP LUITPOLD EQ 50MG PHENYTOIN NA/ML A078277 001 Aug 06, 2007 Feb DISC
>A> @ EQ 50MG PHENYTOIN NA/ML A078277 001 Aug 06, 2007 Feb DISC
>D> AP EQ 50MG PHENYTOIN NA/ML A090099 001 May 13, 2010 Feb DISC
>A> @ EQ 50MG PHENYTOIN NA/ML A090099 001 May 13, 2010 Feb DISC

FULVESTRANT

INJECTABLE; INTRAMUSCULAR
FASLODEX

>D> +! ASTRAZENECA 50MG/ML N021344 001 Apr 25, 2002 Feb CFTG
>A> AP +! 50MG/ML N021344 001 Apr 25, 2002 Feb CFTG
>A> FULVESTRANT
>A> AP AMNEAL PHARMS CO 50MG/ML A210044 001 Mar 04, 2019 Feb NFTG

FUROSEMIDE

TABLET;ORAL
FUROSEMIDE

>A> AB HERITAGE PHARMA 20MG N018413 001 Nov 30, 1983 Feb CAHN
>A> AB 40MG N018413 002 Nov 30, 1983 Feb CAHN
>D> AB IVAX SUB TEVA PHARMS 20MG N018413 001 Nov 30, 1983 Feb CAHN
>D> AB 40MG N018413 002 Nov 30, 1983 Feb CAHN

GALLIUM CITRATE GA-67

INJECTABLE; INJECTION
GALLIUM CITRATE GA 67

BS CURIUM 2mCi/ML N018058 001 Jan CAHN

GANCICLOVIR SODIUM

INJECTABLE; INJECTION
GANCICLOVIR

>D> AP LUITPOLD EQ 500MG BASE/VIAL A202624 001 Sep 18, 2013 Feb DISC
>A> @ EQ 500MG BASE/VIAL A202624 001 Sep 18, 2013 Feb DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

AP FRESENIUS KABI USA EQ 200MG BASE/VIAL A090799 001 Jul 25, 2011 Jan CAHN
AP EQ 1GM BASE/VIAL A090799 002 Jul 25, 2011 Jan CAHN
AP EQ 2GM BASE/VIAL A090799 003 May 16, 2011 Jan CAHN
>A> AP INGENUS PHARMS LLC 200MG/5.26ML (38MG/ML) A210383 001 Feb 14, 2019 Feb NEWA
>A> AP 1GM/26.3ML (38MG/ML) A210383 002 Feb 14, 2019 Feb NEWA
>A> AP 2GM/52.6ML (38MG/ML) A210383 003 Feb 14, 2019 Feb NEWA
>D> AP LUITPOLD EQ 200MG BASE/VIAL A202031 001 May 07, 2013 Feb DISC
>A> @ EQ 200MG BASE/VIAL A202031 001 May 07, 2013 Feb DISC
>D> AP EQ 1GM BASE/VIAL A202031 002 May 07, 2013 Feb DISC
>A> @ EQ 1GM BASE/VIAL A202031 002 May 07, 2013 Feb DISC
>A> AP SHILPA MEDICARE LTD EQ 200MG BASE/VIAL A207575 001 Feb 22, 2019 Feb NEWA
>A> AP EQ 1GM BASE/VIAL A207575 002 Feb 22, 2019 Feb NEWA

>D> GLASDEGIB

>D> TABLET;ORAL
>D> DAURISMO

>D> + PFIZER INC 25MG N210656 001 Nov 21, 2018 Feb CAIN
>D> +! 100MG N210656 002 Nov 21, 2018 Feb CAIN

>A> GLASDEGIB MALEATE

>A> TABLET;ORAL
>A> DAURISMO

>A> + PFIZER INC EQ 25MG BASE N210656 001 Nov 21, 2018 Feb CAIN
>A> +! EQ 100MG BASE N210656 002 Nov 21, 2018 Feb CAIN

GLIPIZIDE

		TABLET;ORAL							
		GLIPIZIDE							
>A>	@	BEXIMCO PHARMS USA	5MG	A074542	001	Jun 20, 1995	Feb	CAHN	
>A>	@		10MG	A074542	002	Jun 20, 1995	Feb	CAHN	
>D>	@	SANDOZ	5MG	A074542	001	Jun 20, 1995	Feb	CAHN	
>D>	@		10MG	A074542	002	Jun 20, 1995	Feb	CAHN	
		TABLET, EXTENDED RELEASE;ORAL							
		GLIPIZIDE							
>D>	AB	MYLAN PHARMS INC	2.5MG	A202298	001	May 19, 2015	Feb	DISC	
>A>	@		2.5MG	A202298	001	May 19, 2015	Feb	DISC	
>D>	AB		5MG	A202298	002	May 19, 2015	Feb	DISC	
>A>	@		5MG	A202298	002	May 19, 2015	Feb	DISC	
>D>	AB		10MG	A202298	003	May 19, 2015	Feb	DISC	
>A>	@		10MG	A202298	003	May 19, 2015	Feb	DISC	

GLYBURIDE

		TABLET;ORAL							
		GLYBURIDE							
>A>	AB1	ORIENT PHARMA CO LTD	1.25MG	A206483	001	Feb 22, 2019	Feb	NEWA	
>A>	AB1		2.5MG	A206483	002	Feb 22, 2019	Feb	NEWA	
>A>	AB1		5MG	A206483	003	Feb 22, 2019	Feb	NEWA	

GLYCEROL PHENYLBUTYRATE

		LIQUID;ORAL							
		RAVICTI							
>A>	+	HORIZON THERAP	1.1GM/ML	N203284	001	Feb 01, 2013	Feb	CAHN	
>D>	+	HORIZON THERAPS INC	1.1GM/ML	N203284	001	Feb 01, 2013	Feb	CAHN	

GRANISETRON HYDROCHLORIDE

		INJECTABLE;INJECTION							
		GRANISETRON HYDROCHLORIDE							
>D>	AP	LUITPOLD	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A091274	001	Sep 22, 2010	Feb	DISC	
>A>	@		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A091274	001	Sep 22, 2010	Feb	DISC	
		TABLET;ORAL							
		GRANISETRON HYDROCHLORIDE							
	@	TEVA PHARMS	EQ 1MG BASE	A078080	001	Dec 31, 2007	Jan	DISC	
AB	!	WEST-WARD PHARMS INT	EQ 1MG BASE	A077842	001	Dec 31, 2007	Jan	CHRS	

HALOBETASOL PROPIONATE

		LOTION;TOPICAL							
		BRYHALI							
	+	DOW PHARM	0.01%	N209355	001	Nov 06, 2018	Jan	CHRS	
	+		0.01%	N209355	001	Nov 06, 2018	Jan	CRLD	

HALOPERIDOL

		TABLET;ORAL							
		HALOPERIDOL							
	!	MYLAN	2MG	A070278	001	Jun 10, 1986	Jan	CTEC	
AB	!		2MG	A070278	001	Jun 10, 1986	Jan	CHRS	
	@	SANDOZ	2MG	A071208	001	Nov 17, 1986	Jan	DISC	

HEPARIN SODIUM

		INJECTABLE;INJECTION							
		HEPARIN SODIUM							
>A>	AP	+	HIKMA	1,000 UNITS/ML	N017037	001		Feb	CAHN
>A>	AP	+		5,000 UNITS/ML	N017037	002		Feb	CAHN
>A>	@			5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Feb	CAHN
>A>	AP	+		10,000 UNITS/ML	N017037	003		Feb	CAHN
>D>	AP	+	WEST-WARD PHARMS INT	1,000 UNITS/ML	N017037	001		Feb	CAHN
>D>	AP	+		5,000 UNITS/ML	N017037	002		Feb	CAHN
>D>	@			5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Feb	CAHN
>D>	AP	+		10,000 UNITS/ML	N017037	003		Feb	CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

		SYRUP;ORAL							
		HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE							
	@	TORRENT	1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017	Jan	CAHN	

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDRALAZINE HYDROCHLORIDE

>D>	AP	LUITPOLD	20MG/ML	A 040136	001	Jun 30, 1997	Feb	DISC
>A>		@	20MG/ML	A 040136	001	Jun 30, 1997	Feb	DISC

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL
LISINAPRIL AND HYDROCHLOROTHIAZIDE

>A>	AB	HERITAGE PHARMA	12.5MG; 10MG	A 075776	001	Jul 01, 2002	Feb	CAHN
>A>	AB		12.5MG; 20MG	A 075776	002	Jul 01, 2002	Feb	CAHN
>A>	AB		25MG; 20MG	A 075776	003	Jul 01, 2002	Feb	CAHN
>D>	AB	IVAX SUB TEVA PHARMS	12.5MG; 10MG	A 075776	001	Jul 01, 2002	Feb	CAHN
>D>	AB		12.5MG; 20MG	A 075776	002	Jul 01, 2002	Feb	CAHN
>D>	AB		25MG; 20MG	A 075776	003	Jul 01, 2002	Feb	CAHN

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB		ACCORD HLTHCARE	12.5MG; 20MG	A 209281	001	Feb 07, 2019	Jan	NEWA
AB			12.5MG; 40MG	A 209281	002	Feb 07, 2019	Jan	NEWA
AB			25MG; 40MG	A 209281	003	Feb 07, 2019	Jan	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
QUINARETIC

>D>	AB	GAVIS PHARMS	12.5MG; EQ 10MG BASE	A 076374	001	Mar 31, 2004	Feb	CAHN
>D>	AB		12.5MG; EQ 20MG BASE	A 076374	002	Mar 31, 2004	Feb	CAHN
>D>	AB		25MG; EQ 20MG BASE	A 076374	003	Mar 31, 2004	Feb	CAHN
>A>	AB	LUPIN	12.5MG; EQ 10MG BASE	A 076374	001	Mar 31, 2004	Feb	CAHN
>A>	AB		12.5MG; EQ 20MG BASE	A 076374	002	Mar 31, 2004	Feb	CAHN
>A>	AB		25MG; EQ 20MG BASE	A 076374	003	Mar 31, 2004	Feb	CAHN

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL
TELMISARTAN AND HYDROCHLOROTHIAZIDE

>A>	AB	GLENMARK PHARMS LTD	12.5MG; 40MG	A 202544	001	Mar 04, 2019	Feb	NEWA
>A>	AB		12.5MG; 80MG	A 202544	002	Mar 04, 2019	Feb	NEWA
>A>	AB		25MG; 80MG	A 202544	003	Mar 04, 2019	Feb	NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		ZYDUS PHARMS USA INC	25MG; 37.5MG	A 208358	001	Feb 11, 2019	Jan	NEWA
----	--	----------------------	--------------	----------	-----	--------------	-----	------

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL
HYDROCODONE BITARTRATE AND IBUPROFEN

>D>	AB	TEVA	7.5MG; 200MG	A 076023	001	Apr 11, 2003	Feb	DISC
>A>		@	7.5MG; 200MG	A 076023	001	Apr 11, 2003	Feb	DISC

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL
HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>D>	AA	TORRENT	5MG/5ML; 60MG/5ML	A 206661	001	Jan 23, 2019	Feb	DISC
>A>		@	5MG/5ML; 60MG/5ML	A 206661	001	Jan 23, 2019	Feb	DISC
	AA		5MG/5ML; 60MG/5ML	A 206661	001	Jan 23, 2019	Jan	NEWA
	AA		5MG/5ML; 60MG/5ML	A 206661	001	Jan 23, 2019	Jan	NEWA

HYDROCORTISONE

CREAM; TOPICAL
NUTRACORT

>A>		@ BAUSCH	0.5%	A 080442	002		Feb	CAHN
>A>		@	1%	A 080442	003		Feb	CAHN
>D>		@ DOW PHARM	0.5%	A 080442	002		Feb	CAHN
>D>		@	1%	A 080442	003		Feb	CAHN

LOTION; TOPICAL
CETACORT

>A>		@ BAUSCH	0.5%	A 080426	002		Feb	CAHN
>A>		@	1%	A 080426	001		Feb	CAHN
>D>		@ DOW PHARM	0.5%	A 080426	002		Feb	CAHN

LOTION; TOPICAL
 CETACORT
 >D> @ 1% A080426 001 Feb CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL
 HYDROXYCHLOROQUINE SULFATE
 AB LAURUS LABS LTD 200MG A210959 001 Jan 15, 2019 Jan CAHN
 >D> AB LUPIN LTD 200MG A210543 001 Jul 06, 2018 Feb DISC
 >A> @ 200MG A210543 001 Jul 06, 2018 Feb DISC

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC
 LACRISERT
 +! VALEANT PHARMS INTL 5MG N018771 001 Jan CAHN

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION
 HYDROXYZINE HYDROCHLORIDE
 >D> ! LUITPOLD 50MG/ML A087408 002 Feb DISC
 >A> @ 50MG/ML A087408 002 Feb DISC
 SYRUP; ORAL
 HYDROXYZINE HYDROCHLORIDE
 >A> AA TORRENT 10MG/5ML A210634 001 Feb 26, 2019 Feb NEWA
 TABLET; ORAL
 HYDROXYZINE HYDROCHLORIDE
 AB EPIC PHARMA LLC 10MG A040604 002 Dec 28, 2004 Jan CAHN
 AB 25MG A040604 003 Dec 28, 2004 Jan CAHN
 AB 50MG A040604 001 Dec 28, 2004 Jan CAHN
 >A> AB KVK TECH 25MG A040786 002 Mar 20, 2007 Feb CMS1
 >A> AB 50MG A040786 003 Mar 20, 2007 Feb CMS1

HYDROXYZINE PAMOATE

CAPSULE; ORAL
 HYDROXYZINE PAMOATE
 >A> @ BEXIMCO PHARMS USA EQ 25MG HYDROCHLORIDE A081127 001 Jun 28, 1991 Feb CAHN
 >D> @ SANDOZ EQ 25MG HYDROCHLORIDE A081127 001 Jun 28, 1991 Feb CAHN

IBUPROFEN

SOLUTION; INTRAVENOUS
 CALDOLOR
 +! CUMBERLAND PHARMS 800MG/200ML (4MG/ML) N022348 003 Jan 25, 2019 Jan NEWA

IBUTILIDE FUMARATE

INJECTABLE; INJECTION
 IBUTILIDE FUMARATE
 >D> AP LUITPOLD 0.1MG/ML A090240 001 Jan 11, 2010 Feb DISC
 >A> @ 0.1MG/ML A090240 001 Jan 11, 2010 Feb DISC

IMATINIB MESYLATE

TABLET; ORAL
 IMATINIB MESYLATE
 >A> AB AMNEAL PHARMS EQ 100MG BASE A207495 001 Feb 08, 2019 Feb NEWA
 >A> AB EQ 400MG BASE A207495 002 Feb 08, 2019 Feb NEWA
 >A> AB BRECKENRIDGE PHARM EQ 100MG BASE A205990 001 Feb 08, 2019 Feb NEWA
 >A> AB EQ 400MG BASE A205990 002 Feb 08, 2019 Feb NEWA
 >A> AB NATCO PHARMA LTD EQ 100MG BASE A207818 001 Mar 01, 2019 Feb NEWA
 >A> AB EQ 400MG BASE A207818 002 Mar 01, 2019 Feb NEWA
 AB SHILPA MEDICARE LTD EQ 100MG BASE A208302 001 Jan 17, 2019 Jan NEWA
 AB EQ 400MG BASE A208302 002 Jan 17, 2019 Jan NEWA
 AB WOCKHARDT BIO AG EQ 100MG BASE A208429 001 Jan 17, 2019 Jan NEWA
 AB EQ 400MG BASE A208429 002 Jan 17, 2019 Jan NEWA

INDIUM IN-111 CHLORIDE

INJECTABLE; INJECTION
 INDIUM IN 111 CHLORIDE
 +! CURIUM 5mCi/0.5ML N019841 001 Sep 27, 1994 Jan CAHN

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION
OCTREOSCAN

+! CURIUM 3mCi/ML N020314 001 Jun 02, 1994 Jan CAHN

INDOMETHACIN

CAPSULE; ORAL
INDOCIN

>A> + @ EGALET 25MG N016059 001 Feb CAHN
 >A> + @ 50MG N016059 002 Feb CAHN
 >D> + @ IROKO PHARMS LLC 25MG N016059 001 Feb CAHN
 >D> + @ 50MG N016059 002 Feb CAHN

INDOMETHACIN

>A> AB HERITAGE PHARMA 25MG A070719 001 Feb 12, 1986 Feb CAHN
 >A> AB 50MG A070756 001 Feb 12, 1986 Feb CAHN
 >D> AB IVAX SUB TEVA PHARMS 25MG A070719 001 Feb 12, 1986 Feb CAHN
 >D> AB 50MG A070756 001 Feb 12, 1986 Feb CAHN

TIVORBEX

>A> + EGALET 20MG N204768 001 Feb 24, 2014 Feb CAHN
 >A> +! 40MG N204768 002 Feb 24, 2014 Feb CAHN
 >D> + IROKO PHARMS LLC 20MG N204768 001 Feb 24, 2014 Feb CAHN
 >D> +! 40MG N204768 002 Feb 24, 2014 Feb CAHN

CAPSULE, EXTENDED RELEASE; ORAL
INDOCIN SR

>A> + @ EGALET 75MG N018185 001 Feb 23, 1982 Feb CAHN
 >D> + @ IROKO PHARMS 75MG N018185 001 Feb 23, 1982 Feb CAHN

SUPPOSITORY; RECTAL

INDOCIN

>A> + @ EGALET 50MG N017814 001 Aug 13, 1984 Feb CAHN
 >D> + @ IROKO PHARMS 50MG N017814 001 Aug 13, 1984 Feb CAHN

SUSPENSION; ORAL

INDOCIN

>A> +! EGALET 25MG/5ML N018332 001 Oct 10, 1985 Feb CAHN
 >D> +! IROKO PHARMS 25MG/5ML N018332 001 Oct 10, 1985 Feb CAHN

IOPROMIDE

INJECTABLE; INJECTION
ULTRAVIST (PHARMACY BULK)

>D> +! BAYER HLTHCARE 49.9% N021425 003 Mar 12, 2004 Feb DISC
 >A> + @ 49.9% N021425 003 Mar 12, 2004 Feb DISC
 >D> ULTRAVIST 240
 >D> +! BAYER HLTHCARE 49.9% N020220 003 May 10, 1995 Feb DISC
 >A> + @ 49.9% N020220 003 May 10, 1995 Feb DISC

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
IRINOTECAN HYDROCHLORIDE

AP FRESENIUS KABI USA 40MG/2ML (20MG/ML) A078188 001 Feb 27, 2008 Jan CAHN
 AP 100MG/5ML (20MG/ML) A078188 002 Feb 27, 2008 Jan CAHN

KETOCONAZOLE

GEL; TOPICAL
XOLEGEL

>A> +! ALMIRALL 2% N021946 001 Jul 28, 2006 Feb CAHN
 >D> +! AQUA PHARMS 2% N021946 001 Jul 28, 2006 Feb CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

>D> @ WEST-WARD PHARMS INT 15MG/ML A075772 001 Jul 21, 2004 Feb CMFD
 >A> AP 15MG/ML A075772 001 Jul 21, 2004 Feb CMFD
 >D> @ 30MG/ML A075772 002 Jul 21, 2004 Feb CMFD
 >A> AP 30MG/ML A075772 002 Jul 21, 2004 Feb CMFD

LABETALOL HYDROCHLORIDE

TABLET; ORAL
LABETALOL HYDROCHLORIDE

>A> AB HERITAGE PHARMA 100MG A074787 001 Aug 03, 1998 Feb CAHN
 >A> AB 200MG A074787 002 Aug 03, 1998 Feb CAHN
 >A> AB 300MG A074787 003 Aug 03, 1998 Feb CAHN
 AB INVATECH PHARMA 100MG A207863 001 Feb 04, 2019 Jan NEWA

TABLET;ORAL

LABETALOL HYDROCHLORIDE

AB		200MG	A207863	002	Feb 04, 2019	Jan NEWA
AB		300MG	A207863	003	Feb 04, 2019	Jan NEWA
>D>	AB	IVAX SUB TEVA PHARMS 100MG	A074787	001	Aug 03, 1998	Feb CAHN
>D>	AB	200MG	A074787	002	Aug 03, 1998	Feb CAHN
>D>	AB	300MG	A074787	003	Aug 03, 1998	Feb CAHN
TRANDATE						
AB	+	CNTY LINE PHARMS 100MG	N018716	001	May 24, 1985	Jan CRLD
AB	+	200MG	N018716	002	Aug 01, 1984	Jan CRLD
AB	+	300MG	N018716	003	Aug 01, 1984	Jan CRLD

LACTULOSE

SOLUTION;ORAL

LACTULOSE

AA	@	BAJAJ 10GM/15ML	A075911	001	Feb 21, 2002	Jan CAHN
		TORRENT 10GM/15ML	A207786	001	Jun 11, 2018	Jan CAHN
SOLUTION;ORAL, RECTAL						
LACTULOSE						
AA	@	BAJAJ 10GM/15ML	A076645	001	Jul 28, 2003	Jan CAHN
		TORRENT 10GM/15ML	A203762	001	Mar 27, 2015	Jan CAHN

LAMIVUDINE

TABLET;ORAL

LAMIVUDINE

>A>	AB	MYLAN LABS LTD 150MG	A078545	001	Mar 05, 2019	Feb NEWA
>A>	AB	300MG	A078545	002	Mar 05, 2019	Feb NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

LAMIVUDINE AND ZIDOVUDINE

	@	MYLAN PHARMS INC 150MG;300MG	A204005	001	Aug 28, 2014	Jan DISC
--	---	------------------------------	---------	-----	--------------	----------

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

AB		ALKEM LABS LTD 15MG	A207394	001	Jan 18, 2019	Jan NEWA
AB		30MG	A207394	002	Jan 18, 2019	Jan NEWA
>D>	AB	KRKA TOVARNA ZDRAVIL 15MG	A091212	001	Sep 16, 2013	Feb DISC
>A>		@ 15MG	A091212	001	Sep 16, 2013	Feb DISC
>D>	AB	30MG	A091212	002	Sep 16, 2013	Feb DISC
>A>		@ 30MG	A091212	002	Sep 16, 2013	Feb DISC

LAROTRECTINIB

CAPSULE;ORAL

VITRAKVI

>A>	+	BAYER HLTHCARE 25MG	N210861	001	Nov 26, 2018	Feb CAHN
>A>	+	! 100MG	N210861	002	Nov 26, 2018	Feb CAHN
>D>	+	LOXO ONCOLOGY INC 25MG	N210861	001	Nov 26, 2018	Feb CAHN
>D>	+	! 100MG	N210861	002	Nov 26, 2018	Feb CAHN

SOLUTION;ORAL

VITRAKVI

>A>	+	! BAYER HEALTHCARE 20MG/ML	N211710	001	Nov 26, 2018	Feb CAHN
>D>	+	! LOXO ONCOLOGY INC 20MG/ML	N211710	001	Nov 26, 2018	Feb CAHN

LETROZOLE

TABLET;ORAL

LETROZOLE

>D>	AB	FRESENIUS KABI ONCOL 2.5MG	A090491	001	Jun 03, 2011	Feb CAHN
>A>	AB	FRESENIUS KABI USA 2.5MG	A090491	001	Jun 03, 2011	Feb CAHN

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION

LEUCOVORIN CALCIUM

>D>	AP	INGENUS PHARMS LLC EQ 10MG BASE/VIAL	A210917	001	Nov 23, 2018	Feb CPOT
>A>	AP	EQ 10MG BASE/ML	A210917	001	Nov 23, 2018	Feb CPOT

LEVOCARNITINE

TABLET;ORAL

LEVOCARNITINE

>D>	AB	ANDA REPOSITORY	330MG	A076858	001	Sep 20, 2004	Feb CAHN
>A>	AB	RISING PHARMS	330MG	A076858	001	Sep 20, 2004	Feb CAHN

LEVOFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

>A>		LEVOFLOXACIN					
>A>		MICRO LABS LTD INDIA	1.5%	A205600	001	Feb 27, 2019	Feb NEWA

TABLET;ORAL

LEVOFLOXACIN

AB		HEC PHARM	250MG	A204968	001	Feb 05, 2019	Jan NEWA
AB			500MG	A204968	002	Feb 05, 2019	Jan NEWA
AB			750MG	A204968	003	Feb 05, 2019	Jan NEWA

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

FETZIMA

AB	+	ALLERGAN SALES LLC	EQ 20MG BASE	N204168	001	Jul 25, 2013	Jan CFTG
AB	+		EQ 40MG BASE	N204168	002	Jul 25, 2013	Jan CFTG
AB	+		EQ 80MG BASE	N204168	003	Jul 25, 2013	Jan CFTG
AB	+		EQ 120MG BASE	N204168	004	Jul 25, 2013	Jan CFTG

LEVOMILNACIPRAN HYDROCHLORIDE

AB		AMNEAL PHARMS CO	EQ 20MG BASE	A210790	001	Feb 04, 2019	Jan NFTG
AB			EQ 40MG BASE	A210790	002	Feb 04, 2019	Jan NFTG
AB			EQ 80MG BASE	A210790	003	Feb 04, 2019	Jan NFTG
AB			EQ 120MG BASE	A210790	004	Feb 04, 2019	Jan NFTG

LEVORPHANOL TARTRATE

TABLET;ORAL

LEVORPHANOL TARTRATE

>D>		SENTYNL THERAPS INC	1MG	A074278	002	Jun 18, 2018	Feb DISC
>A>		@	1MG	A074278	002	Jun 18, 2018	Feb DISC
>D>			3MG	A074278	003	Jun 18, 2018	Feb DISC
>A>		@	3MG	A074278	003	Jun 18, 2018	Feb DISC

LEVOTHYROXINE SODIUM

SOLUTION;ORAL

TIROSINT-SOL

+		INSTITUT BIOCHIMIQUE	13MCG/ML	N206977	001	Dec 15, 2016	Jan CMFD
+			25MCG/ML	N206977	002	Dec 15, 2016	Jan CMFD
+			50MCG/ML	N206977	003	Dec 15, 2016	Jan CMFD
+			75MCG/ML	N206977	004	Dec 15, 2016	Jan CMFD
+			88MCG/ML	N206977	005	Dec 15, 2016	Jan CMFD
+			100MCG/ML	N206977	006	Dec 15, 2016	Jan CMFD
+			112MCG/ML	N206977	007	Dec 15, 2016	Jan CMFD
+			125MCG/ML	N206977	008	Dec 15, 2016	Jan CMFD
+			137MCG/ML	N206977	009	Dec 15, 2016	Jan CMFD
+			150MCG/ML	N206977	010	Dec 15, 2016	Jan CMFD
+			175MCG/ML	N206977	011	Dec 15, 2016	Jan CMFD
+			200MCG/ML	N206977	012	Dec 15, 2016	Jan CMFD

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVOTHYROXINE SODIUM

>A>	AB1, AB2	AMNEAL PHARMS LLC	0.025MG	A210831	001	Feb 19, 2019	Feb NEWA
>A>	AB1, AB2		0.05MG	A210831	002	Feb 19, 2019	Feb NEWA
>A>	AB1, AB2		0.075MG	A210831	003	Feb 19, 2019	Feb NEWA
>A>	AB1, AB2		0.088MG	A210831	004	Feb 19, 2019	Feb NEWA
>A>	AB1, AB2		0.1MG	A210831	005	Feb 19, 2019	Feb NEWA
>A>	AB1, AB2		0.112MG	A210831	006	Feb 19, 2019	Feb NEWA
>A>	AB1, AB2		0.125MG	A210831	007	Feb 19, 2019	Feb NEWA
>A>	AB1, AB2		0.137MG	A210831	008	Feb 19, 2019	Feb NEWA

TABLET;ORAL
LEVOTHYROXINE SODIUM

>A>	AB1, AB2	0.15MG	A210831	009	Feb 19, 2019	Feb	NEWA
>A>	AB1, AB2	0.175MG	A210831	010	Feb 19, 2019	Feb	NEWA
>A>	AB1, AB2	0.2MG	A210831	011	Feb 19, 2019	Feb	NEWA
>A>	AB1, AB2	0.3MG	A210831	012	Feb 19, 2019	Feb	NEWA
	AB2	LUPIN ATLANTIS	A209713	001	Jan 18, 2019	Jan	NEWA
	AB2	0.025MG	A209713	002	Jan 18, 2019	Jan	NEWA
	AB2	0.05MG	A209713	003	Jan 18, 2019	Jan	NEWA
	AB2	0.075MG	A209713	004	Jan 18, 2019	Jan	NEWA
	AB2	0.088MG	A209713	005	Jan 18, 2019	Jan	NEWA
	AB2	0.1MG	A209713	006	Jan 18, 2019	Jan	NEWA
	AB2	0.112MG	A209713	007	Jan 18, 2019	Jan	NEWA
	AB2	0.125MG	A209713	008	Jan 18, 2019	Jan	NEWA
	AB2	0.137MG	A209713	009	Jan 18, 2019	Jan	NEWA
	AB2	0.15MG	A209713	010	Jan 18, 2019	Jan	NEWA
	AB2	0.175MG	A209713	011	Jan 18, 2019	Jan	NEWA
	AB2	0.2MG	A209713	012	Jan 18, 2019	Jan	NEWA
	AB2	0.3MG	A209713	012	Jan 18, 2019	Jan	NEWA

THYRO-TABS

>D>	+ @ LLOYD	0.025MG	N021116	001	Oct 24, 2002	Feb	CMFD
>A>	AB2, + AB4	0.025MG	N021116	001	Oct 24, 2002	Feb	CMFD
>D>	+ @	0.05MG	N021116	002	Oct 24, 2002	Feb	CMFD
>A>	AB2, + AB4	0.05MG	N021116	002	Oct 24, 2002	Feb	CMFD
>D>	+ @	0.075MG	N021116	003	Oct 24, 2002	Feb	CMFD
>A>	AB2, + AB4	0.075MG	N021116	003	Oct 24, 2002	Feb	CMFD
>D>	+ @	0.088MG	N021116	010	Oct 24, 2002	Feb	CMFD
>A>	AB2, + AB4	0.088MG	N021116	010	Oct 24, 2002	Feb	CMFD
>D>	+ @	0.1MG	N021116	004	Oct 24, 2002	Feb	CMFD
>A>	AB2, + AB4	0.1MG	N021116	004	Oct 24, 2002	Feb	CMFD
>D>	+ @	0.112MG	N021116	011	Oct 24, 2002	Feb	CMFD
>A>	AB2, + AB4	0.112MG	N021116	011	Oct 24, 2002	Feb	CMFD
>D>	+ @	0.125MG	N021116	005	Oct 24, 2002	Feb	CMFD
>A>	AB2, + AB4	0.125MG	N021116	005	Oct 24, 2002	Feb	CMFD
>D>	+ @	0.137MG	N021116	012	Dec 07, 2004	Feb	CMFD
>A>	AB2, + AB4	0.137MG	N021116	012	Dec 07, 2004	Feb	CMFD
>D>	+ @	0.15MG	N021116	006	Oct 24, 2002	Feb	CMFD
>A>	AB2, + AB4	0.15MG	N021116	006	Oct 24, 2002	Feb	CMFD
>D>	+ @	0.175MG	N021116	007	Oct 24, 2002	Feb	CMFD
>A>	AB2, + AB4	0.175MG	N021116	007	Oct 24, 2002	Feb	CMFD
>D>	+ @	0.2MG	N021116	008	Oct 24, 2002	Feb	CMFD
>A>	AB2, + AB4	0.2MG	N021116	008	Oct 24, 2002	Feb	CMFD
>D>	+ @	0.3MG	N021116	009	Oct 24, 2002	Feb	CMFD
>A>	AB2, +! AB4	0.3MG	N021116	009	Oct 24, 2002	Feb	CMFD

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HYDROCHLORIDE

>D>	AP	LUITPOLD	1%	A091564	001	Aug 14, 2015	Feb	DISC
>A>	@		1%	A091564	001	Aug 14, 2015	Feb	DISC

LISINAPRIL

TABLET;ORAL
LISINAPRIL

>A>	AB	HERITAGE PHARMA	2.5MG	A075752	001	Jul 01, 2002	Feb	CAHN
>A>	AB		5MG	A075752	002	Jul 01, 2002	Feb	CAHN
>A>	AB		10MG	A075752	003	Jul 01, 2002	Feb	CAHN
>A>	AB		20MG	A075752	004	Jul 01, 2002	Feb	CAHN
>A>	AB		30MG	A075752	005	Jul 01, 2002	Feb	CAHN
>A>	AB		40MG	A075752	006	Jul 01, 2002	Feb	CAHN
>D>	AB	IVAX SUB TEVA PHARMS	2.5MG	A075752	001	Jul 01, 2002	Feb	CAHN
>D>	AB		5MG	A075752	002	Jul 01, 2002	Feb	CAHN

TABLET;ORAL
LISINOPRIL

>D>	AB		10MG	A075752	003	Jul 01, 2002	Feb CAHN
>D>	AB		20MG	A075752	004	Jul 01, 2002	Feb CAHN
>D>	AB		30MG	A075752	005	Jul 01, 2002	Feb CAHN
>D>	AB		40MG	A075752	006	Jul 01, 2002	Feb CAHN

LORAZEPAM

CONCENTRATE;ORAL
LORAZEPAM

>D>	AA	ANDA REPOSITORY	2MG/ML	A079244	001	Apr 28, 2009	Feb CAHN
>A>	AA	SAPTALIS PHARMS	2MG/ML	A079244	001	Apr 28, 2009	Feb CAHN

TABLET;ORAL
ATIVAN

>A>	AB	+ BAUSCH	0.5MG	N017794	001		Feb CAHN
>A>	AB	+	1MG	N017794	002		Feb CAHN
>A>	AB	+!	2MG	N017794	003		Feb CAHN
>D>	AB	+ VALEANT INTL	0.5MG	N017794	001		Feb CAHN
>D>	AB	+	1MG	N017794	002		Feb CAHN
>D>	AB	+!	2MG	N017794	003		Feb CAHN

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC
LOTEMAX SM

>A>		+! BAUSCH AND LOMB INC	0.38%	N208219	001	Feb 22, 2019	Feb NEWA
-----	--	------------------------	-------	---------	-----	--------------	----------

LOVASTATIN

TABLET;ORAL
LOVASTATIN

>A>	AB	BEXIMCO PHARMS USA	10MG	A075300	001	Dec 17, 2001	Feb CAHN
>A>	AB		20MG	A075300	002	Dec 17, 2001	Feb CAHN
>A>	AB		40MG	A075300	003	Dec 17, 2001	Feb CAHN
>D>	AB	MYLAN	10MG	A075451	001	Dec 17, 2001	Feb DISC
>A>		@	10MG	A075451	001	Dec 17, 2001	Feb DISC
>D>	AB		20MG	A075451	002	Dec 17, 2001	Feb DISC
>A>		@	20MG	A075451	002	Dec 17, 2001	Feb DISC
>D>	AB		40MG	A075451	003	Dec 17, 2001	Feb DISC
>A>		@	40MG	A075451	003	Dec 17, 2001	Feb DISC
>D>	AB	SANDOZ	10MG	A075300	001	Dec 17, 2001	Feb CAHN
>D>	AB		20MG	A075300	002	Dec 17, 2001	Feb CAHN
>D>	AB		40MG	A075300	003	Dec 17, 2001	Feb CAHN

LOXAPINE HYDROCHLORIDE

CONCENTRATE;ORAL
LOXITANE C

>D>		@ ACTAVIS LABS UT INC	EQ 25MG BASE/ML	N017658	001		Feb CAHN
>A>		@ TEVA BRANDED PHARM	EQ 25MG BASE/ML	N017658	001		Feb CAHN

LOXAPINE SUCCINATE

CAPSULE;ORAL
LOXITANE

>D>		+ @ ACTAVIS LABS UT INC	EQ 5MG BASE	N017525	001		Feb CAHN
>D>		+ @	EQ 10MG BASE	N017525	002		Feb CAHN
>D>		+ @	EQ 25MG BASE	N017525	003		Feb CAHN
>D>		+ @	EQ 50MG BASE	N017525	004		Feb CAHN
>A>		+ @ TEVA BRANDED PHARM	EQ 5MG BASE	N017525	001		Feb CAHN
>A>		+ @	EQ 10MG BASE	N017525	002		Feb CAHN
>A>		+ @	EQ 25MG BASE	N017525	003		Feb CAHN
>A>		+ @	EQ 50MG BASE	N017525	004		Feb CAHN

TABLET;ORAL
LOXITANE

>D>		+ @ ACTAVIS LABS UT INC	EQ 10MG BASE	N017525	006		Feb CAHN
>D>		+ @	EQ 25MG BASE	N017525	007		Feb CAHN
>D>		+ @	EQ 50MG BASE	N017525	008		Feb CAHN
>A>		+ @ TEVA BRANDED PHARM	EQ 10MG BASE	N017525	006		Feb CAHN
>A>		+ @	EQ 25MG BASE	N017525	007		Feb CAHN
>A>		+ @	EQ 50MG BASE	N017525	008		Feb CAHN

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LURASIDONE HYDROCHLORIDE

>A>	@	TORRENT	20MG	A208055	001	Jan 03, 2019	Feb	DISC
>A>	@		40MG	A208055	002	Jan 03, 2019	Feb	DISC
>A>	@		80MG	A208055	003	Jan 03, 2019	Feb	DISC
>A>	@		120MG	A208055	004	Jan 03, 2019	Feb	DISC
>D>	AB	TORRENT PHARMS LTD	20MG	A208055	001	Jan 03, 2019	Feb	DISC
>D>	AB		40MG	A208055	002	Jan 03, 2019	Feb	DISC
>D>	AB		80MG	A208055	003	Jan 03, 2019	Feb	DISC
>D>	AB		120MG	A208055	004	Jan 03, 2019	Feb	DISC

MAGNESIUM SULFATE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

AP	+	FRESENIUS KABI USA	10GM/20ML (500MG/ML)	N019316	003	Jan 29, 2016	Jan	CTEC
AP		HOSPIRA INC	10GM/20ML (500MG/ML)	A202411	001	May 14, 2015	Jan	CTEC

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

ANTIVERT

>D>	+	@	CASPER PHARMA LLC	12.5MG	N010721	006		Feb	CMFD
>A>	AA	+		12.5MG	N010721	006		Feb	CMFD
		+	@	12.5MG	N010721	006		Jan	CRLD
>D>		+	@	25MG	N010721	004		Feb	CMFD
>A>	AA	+		25MG	N010721	004		Feb	CMFD
		+	@	25MG	N010721	004		Jan	CRLD
>D>		+	@	50MG	N010721	001	Jan 20, 1982	Feb	CMFD
>A>	AA	+		50MG	N010721	001	Jan 20, 1982	Feb	CMFD
		+	@	50MG	N010721	001	Jan 20, 1982	Jan	CRLD
				MECLIZINE HYDROCHLORIDE					
AA	!	AMNEAL PHARMS	12.5MG	A201451	001	Feb 23, 2011	Jan	CHRS	
AA	!		25MG	A201451	002	Feb 23, 2011	Jan	CHRS	
>A>	AA	INDICUS PHARMA	12.5MG	A205136	001	Feb 22, 2019	Feb	NEWA	
>A>	AA		25MG	A205136	002	Feb 22, 2019	Feb	NEWA	
>A>			50MG	A205136	003	Feb 22, 2019	Feb	NEWA	

TABLET, CHEWABLE; ORAL

ANTIVERT

>D>	+	@	CASPER PHARMA LLC	25MG	N010721	005		Feb	CMFD
>A>	AA	+		25MG	N010721	005		Feb	CMFD
		+	@	25MG	N010721	005		Jan	CRLD

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

AB		CIPLA	150MG/ML	A210335	001	Jan 25, 2019	Jan	NEWA
----	--	-------	----------	---------	-----	--------------	-----	------

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

>D>	AB	BRECKENRIDGE PHARM	250MG	A090359	001	Feb 05, 2013	Feb	DISC
>A>		@	250MG	A090359	001	Feb 05, 2013	Feb	DISC

MELOXICAM

CAPSULE; ORAL

VIVLODEX

>A>	+	EGALET	5MG	N207233	001	Oct 22, 2015	Feb	CAHN
>A>	+	!	10MG	N207233	002	Oct 22, 2015	Feb	CAHN
>D>	+	IROKO PHARMS LLC	5MG	N207233	001	Oct 22, 2015	Feb	CAHN
>D>	+	!	10MG	N207233	002	Oct 22, 2015	Feb	CAHN

TABLET; ORAL

MELOXICAM

>A>	AB	HERITAGE PHARMA	7.5MG	A077936	001	Jul 19, 2006	Feb	CAHN
>A>	AB		15MG	A077936	002	Jul 19, 2006	Feb	CAHN
>D>	AB	TEVA PHARMS	7.5MG	A077936	001	Jul 19, 2006	Feb	CAHN
>D>	AB		15MG	A077936	002	Jul 19, 2006	Feb	CAHN

METHYLPHENIDATE HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE;ORAL							
>A>	ADHANSIA XR							
>A>	PURDUE PHARMA LP	25MG		N212038	001	Feb 27, 2019	Feb	NEWA
>A>	+	35MG		N212038	002	Feb 27, 2019	Feb	NEWA
>A>	+	45MG		N212038	003	Feb 27, 2019	Feb	NEWA
>A>	+	55MG		N212038	004	Feb 27, 2019	Feb	NEWA
>A>	+	70MG		N212038	005	Feb 27, 2019	Feb	NEWA
>A>	+	85MG		N212038	006	Feb 27, 2019	Feb	NEWA
	FOR SUSPENSION, EXTENDED RELEASE;ORAL							
	METHYLPHENIDATE HYDROCHLORIDE							
	@ ACTAVIS LABS FL INC	5MG/ML		A206049	001	May 17, 2018	Jan	DISC
	QUILLIVANT XR							
>A>	+! NEXTWAVE	5MG/ML		N202100	001	Sep 27, 2012	Feb	CAHN
>D>	+! NEXTWAVE PHARMS	5MG/ML		N202100	001	Sep 27, 2012	Feb	CAHN
	+!	5MG/ML		N202100	001	Sep 27, 2012	Jan	CTEC
	TABLET;ORAL							
	METHYLPHENIDATE HYDROCHLORIDE							
AB	CEDIPROF INC	5MG		A208737	001	Feb 01, 2019	Jan	NEWA
AB		10MG		A208737	002	Feb 01, 2019	Jan	NEWA
AB		20MG		A208737	003	Feb 01, 2019	Jan	NEWA
	@ LANNETT CO INC	5MG		A086429	001		Jan	DISC
	@	10MG		A085799	001		Jan	DISC
	@	20MG		A086428	001		Jan	DISC
	TABLET, EXTENDED RELEASE;ORAL							
	METADATE ER							
	@ LANNETT CO INC	20MG		A089601	001	Jun 01, 1988	Jan	DISC
	METHYLPHENIDATE HYDROCHLORIDE							
AB	! ABHAI LLC	20MG		A207488	002	Jun 09, 2015	Jan	NEWA

METHYLPREDNISOLONE

	TABLET;ORAL							
	METHYLPREDNISOLONE							
>A>	AB LUPIN LTD	2MG		A209097	001	Feb 22, 2019	Feb	NEWA
>A>	AB	4MG		A209097	002	Feb 22, 2019	Feb	NEWA
>A>	AB	8MG		A209097	003	Feb 22, 2019	Feb	NEWA
>A>	AB	16MG		A209097	004	Feb 22, 2019	Feb	NEWA
>A>	AB	32MG		A209097	005	Feb 22, 2019	Feb	NEWA

METOPROLOL TARTRATE

	INJECTABLE;INJECTION							
	METOPROLOL TARTRATE							
>D>	AP LUITPOLD	1MG/ML		A091307	001	Dec 29, 2010	Feb	DISC
>A>	@	1MG/ML		A091307	001	Dec 29, 2010	Feb	DISC

METRONIDAZOLE

	INJECTABLE;INJECTION							
	METRONIDAZOLE IN PLASTIC CONTAINER							
>A>	AP INFORLIFE	500MG/100ML		A206191	001	Feb 25, 2019	Feb	NEWA

MILRINONE LACTATE

	INJECTABLE;INJECTION							
	MILRINONE LACTATE							
>D>	AP GLAND PHARMA LTD	EQ 1MG BASE/ML		A077190	001	Oct 31, 2006	Feb	DISC
>A>	@	EQ 1MG BASE/ML		A077190	001	Oct 31, 2006	Feb	DISC

MINOCYCLINE HYDROCHLORIDE

	TABLET, EXTENDED RELEASE;ORAL							
	MINOCYCLINE HYDROCHLORIDE							
AB	BARR LABS INC	EQ 80MG BASE		A065485	007	Apr 26, 2017	Jan	CMFD
AB		EQ 105MG BASE		A065485	008	Apr 26, 2017	Jan	CMFD

MITOMYCIN

	INJECTABLE;INJECTION							
	MITOMYCIN							
AP	WEST-WARD PHARMS INT	20MG/VIAL		A064117	002	Apr 19, 1995	Jan	CMFD
AP		40MG/VIAL		A064117	003	Jun 02, 1999	Jan	CMFD

MONTELUKAST SODIUM

GRANULE;ORAL

MONTELUKAST SODIUM

>D>	AB	MYLAN PHARMS INC	EQ 4MG BASE/PACKET	A202776	001	Dec 18, 2012	Feb DISC
>A>		@	EQ 4MG BASE/PACKET	A202776	001	Dec 18, 2012	Feb DISC

TABLET;ORAL

MONTELUKAST SODIUM

>D>	AB	VINTAGE PHARMS LLC	EQ 10MG BASE	A091576	001	Aug 03, 2012	Feb DISC
>A>		@	EQ 10MG BASE	A091576	001	Aug 03, 2012	Feb DISC

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

>D>	AB	VINTAGE PHARMS LLC	EQ 4MG BASE	A091588	001	Aug 03, 2012	Feb DISC
>A>		@	EQ 4MG BASE	A091588	001	Aug 03, 2012	Feb DISC
>D>	AB		EQ 5MG BASE	A091588	002	Aug 03, 2012	Feb DISC
>A>		@	EQ 5MG BASE	A091588	002	Aug 03, 2012	Feb DISC

MORPHINE SULFATE

SOLUTION;ORAL

MORPHINE SULFATE

>D>	AA	LANNETT CO INC	10MG/5ML	A202309	001	Nov 25, 2015	Feb DISC
>A>		@	10MG/5ML	A202309	001	Nov 25, 2015	Feb DISC
		@	20MG/5ML	A202310	001	Oct 30, 2015	Jan DISC
		@	100MG/5ML	N201517	001	Jun 23, 2011	Jan DISC

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

>D>	AB	MYLAN PHARMS INC	200MG	A200824	005	Oct 18, 2011	Feb DISC
>A>		@	200MG	A200824	005	Oct 18, 2011	Feb DISC

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

AT1		ALEMBIC PHARMS LTD	EQ 0.5% BASE	A209469	001	Feb 13, 2019	Jan NEWA
-----	--	--------------------	--------------	---------	-----	--------------	----------

MYCOPHENOLATE MOFETIL

SUSPENSION;ORAL

MYCOPHENOLATE MOFETIL

AB		VISTAPHARM	200MG/ML	A210370	001	Feb 12, 2019	Jan NEWA
----	--	------------	----------	---------	-----	--------------	----------

NALBUPHINE HYDROCHLORIDE

INJECTABLE;INJECTION

NALBUPHINE HYDROCHLORIDE

AP		MYLAN LABS LTD	10MG/ML	A206506	001	Feb 06, 2019	Jan NEWA
AP			20MG/ML	A206506	002	Feb 06, 2019	Jan NEWA

NALOXONE HYDROCHLORIDE

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

EVZIO

>D>							
>D>	+	KALEO INC	2MG/0.4ML (2MG/0.4ML)	N209862	001	Oct 19, 2016	Feb CTNA
>A>		EVZIO (AUTOINJECTOR)					
>A>	+	KALEO INC	2MG/0.4ML (2MG/0.4ML)	N209862	001	Oct 19, 2016	Feb CTNA

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

>D>	AB	GAVIS PHARMS	EQ 0.5MG BASE;EQ 50MG BASE	A075735	001	Jul 11, 2001	Feb CAHN
>A>	AB	LUPIN	EQ 0.5MG BASE;EQ 50MG BASE	A075735	001	Jul 11, 2001	Feb CAHN

>D> NANDROLONE DECANOATE

INJECTABLE;INJECTION

NANDROLONE DECANOATE

>D>	!	LUITPOLD	200MG/ML	A091252	001	Aug 30, 2010	Feb DISC
>A>		@	200MG/ML	A091252	001	Aug 30, 2010	Feb DISC

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

AP		AMRING PHARMS	5MG/10ML (0.5MG/ML)	A210989	001	Aug 22, 2018	Jan CAHN
AP			10MG/10ML (1MG/ML)	A210989	002	Aug 22, 2018	Jan CAHN

NIACIN

TABLET, EXTENDED RELEASE;ORAL
NIACIN

>A>	AB	MYLAN PHARMS INC	500MG	A203742	001	Feb 22, 2019	Feb NEWA
>A>	AB		750MG	A203742	002	Feb 22, 2019	Feb NEWA
>A>	AB		1GM	A203742	003	Feb 22, 2019	Feb NEWA

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL
NIFEDIPINE

>A>	AB2	NOVAST LABS	30MG	A210614	001	Mar 12, 2019	Feb NEWA
>A>	AB2		60MG	A210614	002	Mar 12, 2019	Feb NEWA
>A>	AB2		90MG	A210614	003	Mar 12, 2019	Feb NEWA

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL
NITROGLYCERIN

>A>	AB2	HERCON PHARM	0.1MG/HR	A089885	002	Oct 30, 2017	Feb NEWA
>D>	!	MYLAN TECHNOLOGIES	0.1MG/HR	A074559	004	Feb 06, 1998	Feb CTEC
>A>	AB2	!	0.1MG/HR	A074559	004	Feb 06, 1998	Feb CTEC

NYSTATIN

OINTMENT;TOPICAL
NYSTATIN

AT		TORRENT	100,000 UNITS/GM	A211838	001	Jan 28, 2019	Jan NEWA
		POWDER;TOPICAL NYSTATIN					
>D>	AT	GAVIS PHARMS	100,000 UNITS/GM	A065138	001	Jul 23, 2004	Feb CAHN
>A>	AT	LUPIN	100,000 UNITS/GM	A065138	001	Jul 23, 2004	Feb CAHN

OCTREOTIDE ACETATE

INJECTABLE;INJECTION
OCTREOTIDE ACETATE

AP		HERITAGE PHARMS INC	EQ 0.2MG BASE/ML	A203765	001	Sep 07, 2018	Jan CAHN
AP			EQ 1MG BASE/ML	A203765	002	Sep 07, 2018	Jan CAHN

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC
OFLOXACIN

>D>		@ APOTEX INC	0.3%	A076513	001	May 14, 2004	Feb CMFD
>A>	AT		0.3%	A076513	001	May 14, 2004	Feb CMFD

OLANZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

>D>	AB	HEC PHARM	5MG	A208146	001	Jul 02, 2018	Feb DISC
>A>		@	5MG	A208146	001	Jul 02, 2018	Feb DISC
>D>	AB		10MG	A208146	002	Jul 02, 2018	Feb DISC
>A>		@	10MG	A208146	002	Jul 02, 2018	Feb DISC
>D>	AB		15MG	A208146	003	Jul 02, 2018	Feb DISC
>A>		@	15MG	A208146	003	Jul 02, 2018	Feb DISC
>D>	AB		20MG	A208146	004	Jul 02, 2018	Feb DISC
>A>		@	20MG	A208146	004	Jul 02, 2018	Feb DISC

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

>A>	AB	SUNSHINE LAKE	5MG	A211049	001	Feb 22, 2019	Feb NEWA
>A>	AB		20MG	A211049	002	Feb 22, 2019	Feb NEWA
>A>	AB		40MG	A211049	003	Feb 22, 2019	Feb NEWA

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

OMEGA-3-ACID ETHYL ESTERS

>A>	AB	ASCENT PHARMS INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A207420	001	Feb 25, 2019	Feb NEWA
-----	----	-------------------	--	---------	-----	--------------	----------

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

>D>	AP	LUITPOLD	EQ 2MG BASE/ML	A079039	001	Nov 18, 2008	Feb	DISC
>A>		@	EQ 2MG BASE/ML	A079039	001	Nov 18, 2008	Feb	DISC
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE								
>D>	AP	HIKMA FARMACEUTICA	EQ 2MG BASE/ML	A076780	001	Dec 26, 2006	Feb	DISC
>A>		@	EQ 2MG BASE/ML	A076780	001	Dec 26, 2006	Feb	DISC
>D>	AP	LUITPOLD	EQ 2MG BASE/ML	A079032	001	Nov 18, 2008	Feb	DISC
>A>		@	EQ 2MG BASE/ML	A079032	001	Nov 18, 2008	Feb	DISC

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

>D>	AB	MYLAN	EQ 24MG BASE	A076930	004	Jun 25, 2007	Feb	DISC
>A>		@	EQ 24MG BASE	A076930	004	Jun 25, 2007	Feb	DISC

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

NORFLEX

+ @	TELGENT	30MG/ML	N013055	001			Jan	CRLD
-----	---------	---------	---------	-----	--	--	-----	------

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

>D>	AB	GAVIS PHARMS	100MG	A040284	001	Jun 19, 1998	Feb	CAHN
>A>	AB	LUPIN	100MG	A040284	001	Jun 19, 1998	Feb	CAHN

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

OSELTAMIVIR PHOSPHATE

>A>	AB	TEVA PHARMS USA	EQ 6MG BASE/ML	A211125	001	Feb 27, 2019	Feb	NEWA
-----	----	-----------------	----------------	---------	-----	--------------	-----	------

OXALIPLATIN

INJECTABLE; INTRAVENOUS

ELOXATIN

>A>		+ @	SANOFI AVENTIS US	50MG/VIAL	N021492	001	Aug 09, 2002	Feb	CDFR
>A>	AP	+	!	50MG/10ML (5MG/ML)	N021759	001	Jan 31, 2005	Feb	CDFR
>A>		+ @		100MG/VIAL	N021492	002	Aug 09, 2002	Feb	CDFR
>A>	AP	+	!	100MG/20ML (5MG/ML)	N021759	002	Jan 31, 2005	Feb	CDFR
>A>		+ @		200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	Feb	CDFR

OXALIPLATIN

>A>	AP	ACCORD HLTHCARE	50MG/10ML (5MG/ML)	A207474	001	Mar 21, 2017	Feb	CDFR	
>A>	AP		100MG/20ML (5MG/ML)	A207474	002	Mar 21, 2017	Feb	CDFR	
>A>	AP		200MG/40ML (5MG/ML)	A207474	003	Mar 21, 2017	Feb	CDFR	
>A>	AP	ACTAVIS LLC	50MG/10ML (5MG/ML)	A204880	001	Mar 05, 2018	Feb	CDFR	
>A>	AP		100MG/20ML (5MG/ML)	A204880	002	Mar 05, 2018	Feb	CDFR	
>A>	AP	ACTAVIS TOTOWA	50MG/VIAL	A078803	001	Aug 08, 2012	Feb	CDFR	
>A>	AP		100MG/VIAL	A078803	002	Aug 08, 2012	Feb	CDFR	
>A>	AP	CIPLA	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017	Feb	CDFR	
>A>	AP		100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017	Feb	CDFR	
>A>	AP	EUGIA PHARMA	50MG/10ML (5MG/ML)	A205529	001	Sep 06, 2017	Feb	CDFR	
>A>	AP		100MG/20ML (5MG/ML)	A205529	002	Sep 06, 2017	Feb	CDFR	
>A>	AP	FRESENIUS KABI USA	50MG/10ML (5MG/ML)	A078811	001	Jun 10, 2010	Feb	CDFR	
>A>	AP		100MG/20ML (5MG/ML)	A078811	002	Jun 10, 2010	Feb	CDFR	
>A>	AP		50MG/VIAL	A078819	001	Jun 02, 2010	Feb	CDFR	
>A>	AP		50MG/10ML (5MG/ML)	A090030	001	Jan 31, 2017	Feb	CDFR	
>A>	AP		100MG/VIAL	A078819	002	Jun 02, 2010	Feb	CDFR	
>A>	AP		100MG/20ML (5MG/ML)	A090030	002	Jan 31, 2017	Feb	CDFR	
>A>	AP		200MG/40ML (5MG/ML)	A090030	003	Jan 31, 2017	Feb	CDFR	
>A>	AP	GLAND PHARMA LTD	50MG/10ML (5MG/ML)	A207325	001	Feb 10, 2017	Feb	CDFR	
>A>	AP		50MG/VIAL	A207385	001	May 23, 2017	Feb	CDFR	
>A>	AP		50MG/VIAL	A207385	001	May 23, 2017	Feb	CDFR	
>A>	AP		100MG/20ML (5MG/ML)	A207325	002	Feb 10, 2017	Feb	CDFR	
>A>	AP		100MG/VIAL	A207385	002	May 23, 2017	Feb	CDFR	
>A>	AP		100MG/VIAL	A207385	002	May 23, 2017	Feb	CDFR	
>A>	AP		200MG/40ML (5MG/ML)	A207325	003	Oct 18, 2017	Feb	CDFR	
>A>	AP	HOSPIRA INC	50MG/VIAL	A078815	001	Sep 30, 2009	Feb	CDFR	
>A>	AP		100MG/VIAL	A078815	002	Sep 30, 2009	Feb	CDFR	
>A>	AP	HOSPIRA WORLDWIDE	50MG/10ML (5MG/ML)	A078813	001	Aug 07, 2009	Feb	CDFR	
>A>	AP		100MG/20ML (5MG/ML)	A078813	002	Aug 07, 2009	Feb	CDFR	
>A>	AP	INGENUS PHARMS LLC	50MG/10ML (5MG/ML)	A207562	001	Oct 16, 2018	Feb	CDFR	
>A>	AP		100MG/20ML (5MG/ML)	A207562	002	Oct 16, 2018	Feb	CDFR	
>A>	AP	JIANGSU HENGRUI MED	50MG/10ML (5MG/ML)	A203869	001	Jun 18, 2014	Feb	CDFR	
>A>	AP		100MG/20ML (5MG/ML)	A203869	002	Jun 18, 2014	Feb	CDFR	
>A>		@	LUITPOLD	50MG/10ML (5MG/ML)	A204378	001	May 12, 2017	Feb	DISC

>A>	INJECTABLE; INTRAVENOUS							
>A>	OXALIPLATIN							
>A> AP		50MG/10ML (5MG/ML)		A204378	001	May 12, 2017	Feb	CDFR
>A>	@	100MG/20ML (5MG/ML)		A204378	002	May 12, 2017	Feb	DISC
>A> AP		100MG/20ML (5MG/ML)		A204378	002	May 12, 2017	Feb	CDFR
>A> AP	MYLAN LABS LTD	50MG/10ML (5MG/ML)		A091358	001	Aug 07, 2012	Feb	CDFR
>A> AP		50MG/VIAL		A200979	001	Aug 08, 2012	Feb	CDFR
>A> AP		100MG/20ML (5MG/ML)		A091358	002	Aug 07, 2012	Feb	CDFR
>A> AP		100MG/VIAL		A200979	002	Aug 08, 2012	Feb	CDFR
>A> AP		200MG/40ML (5MG/ML)		A091358	003	Nov 14, 2017	Feb	CDFR
>A> AP	QILU PHARM CO LTD	50MG/10ML (5MG/ML)		A204368	001	Jun 07, 2016	Feb	CDFR
>A> AP		50MG/VIAL		A204616	001	May 11, 2016	Feb	CDFR
>A> AP		100MG/20ML (5MG/ML)		A204368	002	Jun 07, 2016	Feb	CDFR
>A> AP		100MG/VIAL		A204616	002	May 11, 2016	Feb	CDFR
>A> AP	!	200MG/40ML (5MG/ML)		A204368	003	Jun 07, 2016	Feb	CDFR
>A> AP	SANDOZ	50MG/10ML (5MG/ML)		A078817	001	Jan 24, 2011	Feb	CDFR
>A>	@	50MG/VIAL		A090849	001	Apr 28, 2011	Feb	CDFR
>A> AP		100MG/20ML (5MG/ML)		A078817	002	Jan 24, 2011	Feb	CDFR
>A>	@	100MG/VIAL		A090849	002	Apr 28, 2011	Feb	CDFR
>A>	@ SANDOZ INC	50MG/10ML (5MG/ML)		A078812	001	Aug 07, 2009	Feb	CDFR
>A>	@	100MG/20ML (5MG/ML)		A078812	002	Aug 07, 2009	Feb	CDFR
>A> AP	! SUN PHARMA GLOBAL	50MG/VIAL		A078818	001	Aug 07, 2009	Feb	CDFR
>A> AP		50MG/10ML (5MG/ML)		A202922	001	Apr 08, 2014	Feb	CDFR
>A> AP	!	100MG/VIAL		A078818	002	Aug 07, 2009	Feb	CDFR
>A> AP		100MG/20ML (5MG/ML)		A202922	002	Apr 08, 2014	Feb	CDFR
>A> AP	+! TEVA PHARMS	50MG/10ML (5MG/ML)		N022160	001	Aug 07, 2009	Feb	CDFR
>A> AP	+!	100MG/20ML (5MG/ML)		N022160	002	Aug 07, 2009	Feb	CDFR
>D>	INJECTABLE; IV (INFUSION)							
>D>	ELOXATIN							
>D>	+ @ SANOFI AVENTIS US	50MG/VIAL		N021492	001	Aug 09, 2002	Feb	CDFR
>D> AP	+!	50MG/10ML (5MG/ML)		N021759	001	Jan 31, 2005	Feb	CDFR
>D>	+ @	100MG/VIAL		N021492	002	Aug 09, 2002	Feb	CDFR
>D> AP	+!	100MG/20ML (5MG/ML)		N021759	002	Jan 31, 2005	Feb	CDFR
>D>	+ @	200MG/40ML (5MG/ML)		N021759	003	Nov 17, 2006	Feb	CDFR
>D>	OXALIPLATIN							
>D> AP	ACCORD HLTHCARE	50MG/10ML (5MG/ML)		A207474	001	Mar 21, 2017	Feb	CDFR
>D> AP		100MG/20ML (5MG/ML)		A207474	002	Mar 21, 2017	Feb	CDFR
>D> AP		200MG/40ML (5MG/ML)		A207474	003	Mar 21, 2017	Feb	CDFR
>D> AP	ACTAVIS LLC	50MG/10ML (5MG/ML)		A204880	001	Mar 05, 2018	Feb	CDFR
>D> AP		100MG/20ML (5MG/ML)		A204880	002	Mar 05, 2018	Feb	CDFR
>D> AP	ACTAVIS TOTOWA	50MG/VIAL		A078803	001	Aug 08, 2012	Feb	CDFR
>D> AP		100MG/VIAL		A078803	002	Aug 08, 2012	Feb	CDFR
>D> AP	CIPLA	50MG/10ML (5MG/ML)		A208523	001	Feb 10, 2017	Feb	CDFR
>D> AP		100MG/20ML (5MG/ML)		A208523	002	Feb 10, 2017	Feb	CDFR
>D> AP	EUGIA PHARMA	50MG/10ML (5MG/ML)		A205529	001	Sep 06, 2017	Feb	CDFR
>D> AP		100MG/20ML (5MG/ML)		A205529	002	Sep 06, 2017	Feb	CDFR
>D> AP	FRESENIUS KABI USA	50MG/10ML (5MG/ML)		A078811	001	Jun 10, 2010	Feb	CDFR
>D> AP		100MG/20ML (5MG/ML)		A078811	002	Jun 10, 2010	Feb	CDFR
>D> AP		50MG/VIAL		A078819	001	Jun 02, 2010	Feb	CDFR
>D> AP		50MG/10ML (5MG/ML)		A090030	001	Jan 31, 2017	Feb	CDFR
>D> AP		100MG/VIAL		A078819	002	Jun 02, 2010	Feb	CDFR
>D> AP		100MG/20ML (5MG/ML)		A090030	002	Jan 31, 2017	Feb	CDFR
>D> AP		200MG/40ML (5MG/ML)		A090030	003	Jan 31, 2017	Feb	CDFR
>D> AP	GLAND PHARMA LTD	50MG/10ML (5MG/ML)		A207325	001	Feb 10, 2017	Feb	CDFR
>D> AP		50MG/VIAL		A207385	001	May 23, 2017	Feb	CDFR
>D> AP		50MG/VIAL		A207385	001	May 23, 2017	Feb	CDFR
>D> AP		100MG/20ML (5MG/ML)		A207325	002	Feb 10, 2017	Feb	CDFR
>D> AP		100MG/VIAL		A207385	002	May 23, 2017	Feb	CDFR
>D> AP		100MG/VIAL		A207385	002	May 23, 2017	Feb	CDFR
>D> AP		200MG/40ML (5MG/ML)		A207325	003	Oct 18, 2017	Feb	CDFR
>D> AP	HOSPIRA INC	50MG/VIAL		A078815	001	Sep 30, 2009	Feb	CDFR
>D> AP		100MG/VIAL		A078815	002	Sep 30, 2009	Feb	CDFR
>D> AP	HOSPIRA WORLDWIDE	50MG/10ML (5MG/ML)		A078813	001	Aug 07, 2009	Feb	CDFR
>D> AP		100MG/20ML (5MG/ML)		A078813	002	Aug 07, 2009	Feb	CDFR
>D> AP	INGENUS PHARMS LLC	50MG/10ML (5MG/ML)		A207562	001	Oct 16, 2018	Feb	CDFR
>D> AP		100MG/20ML (5MG/ML)		A207562	002	Oct 16, 2018	Feb	CDFR
>D> AP	JIANGSU HENGRUI MED	50MG/10ML (5MG/ML)		A203869	001	Jun 18, 2014	Feb	CDFR
>D> AP		100MG/20ML (5MG/ML)		A203869	002	Jun 18, 2014	Feb	CDFR
>D> AP	LUITPOLD	50MG/10ML (5MG/ML)		A204378	001	May 12, 2017	Feb	DISC
>D> AP		50MG/10ML (5MG/ML)		A204378	001	May 12, 2017	Feb	CDFR
>D> AP		100MG/20ML (5MG/ML)		A204378	002	May 12, 2017	Feb	CDFR
>D> AP		100MG/20ML (5MG/ML)		A204378	002	May 12, 2017	Feb	DISC
>D> AP	MYLAN LABS LTD	50MG/10ML (5MG/ML)		A091358	001	Aug 07, 2012	Feb	CDFR
>D> AP		50MG/VIAL		A200979	001	Aug 08, 2012	Feb	CDFR

>D>	INJECTABLE;IV (INFUSION)							
>D>	OXALIPLATIN							
>D> AP		100MG/20ML (5MG/ML)		A091358	002	Aug 07, 2012	Feb	CDFR
>D> AP		100MG/VIAL		A200979	002	Aug 08, 2012	Feb	CDFR
>D> AP		200MG/40ML (5MG/ML)		A091358	003	Nov 14, 2017	Feb	CDFR
>D> AP	QILU PHARM CO LTD	50MG/10ML (5MG/ML)		A204368	001	Jun 07, 2016	Feb	CDFR
>D> AP		50MG/VIAL		A204616	001	May 11, 2016	Feb	CDFR
>D> AP		100MG/20ML (5MG/ML)		A204368	002	Jun 07, 2016	Feb	CDFR
>D> AP		100MG/VIAL		A204616	002	May 11, 2016	Feb	CDFR
>D> AP	!	200MG/40ML (5MG/ML)		A204368	003	Jun 07, 2016	Feb	CDFR
>D> AP	SANDOZ	50MG/10ML (5MG/ML)		A078817	001	Jan 24, 2011	Feb	CDFR
>D>	@	50MG/VIAL		A090849	001	Apr 28, 2011	Feb	CDFR
>D> AP		100MG/20ML (5MG/ML)		A078817	002	Jan 24, 2011	Feb	CDFR
>D>	@	100MG/VIAL		A090849	002	Apr 28, 2011	Feb	CDFR
>D>	@ SANDOZ INC	50MG/10ML (5MG/ML)		A078812	001	Aug 07, 2009	Feb	CDFR
>D>	@	100MG/20ML (5MG/ML)		A078812	002	Aug 07, 2009	Feb	CDFR
>D> AP	!	SUN PHARMA GLOBAL	50MG/VIAL	A078818	001	Aug 07, 2009	Feb	CDFR
>D> AP		50MG/10ML (5MG/ML)		A202922	001	Apr 08, 2014	Feb	CDFR
>D> AP	!		100MG/VIAL	A078818	002	Aug 07, 2009	Feb	CDFR
>D> AP		100MG/20ML (5MG/ML)		A202922	002	Apr 08, 2014	Feb	CDFR
>A> AP		200MG/40ML (5MG/ML)		A202922	003	Feb 15, 2019	Feb	NEWA
>D> AP	+!	TEVA PHARMS	50MG/10ML (5MG/ML)	N022160	001	Aug 07, 2009	Feb	CDFR
>D> AP	+!		100MG/20ML (5MG/ML)	N022160	002	Aug 07, 2009	Feb	CDFR

OXYBUTYNIN CHLORIDE

	TABLET;ORAL							
	OXYBUTYNIN CHLORIDE							
AB	INVATECH PHARMA	5MG		A211062	001	Feb 06, 2019	Jan	NEWA
	TABLET, EXTENDED RELEASE;ORAL							
	OXYBUTYNIN CHLORIDE							
>A> AB	AJANTA PHARMA LTD	5MG		A211655	001	Feb 28, 2019	Feb	NEWA
>A> AB		10MG		A211655	002	Feb 28, 2019	Feb	NEWA
>A> AB		15MG		A211655	003	Feb 28, 2019	Feb	NEWA

OXYCODONE HYDROCHLORIDE

	SOLUTION;ORAL							
	OXYCODONE HYDROCHLORIDE							
>A> AA	ALKEM LABS LTD	5MG/5ML		A211748	001	Feb 07, 2019	Feb	NEWA
AA		100MG/5ML		A211749	001	Feb 04, 2019	Jan	NEWA
	@ LANNETT CO INC	100MG/5ML		A204085	001	Sep 09, 2014	Jan	DISC
AA	PHARM ASSOC	5MG/ML		A206914	001	Feb 01, 2019	Jan	NEWA

PAMIDRONATE DISODIUM

	INJECTABLE;INJECTION							
	PAMIDRONATE DISODIUM							
	@ SUN PHARMA GLOBAL	30MG/VIAL		A077703	001	Dec 24, 2008	Jan	DISC
	@	90MG/VIAL		A077703	002	Dec 24, 2008	Jan	DISC

PANTOPRAZOLE SODIUM

	TABLET, DELAYED RELEASE;ORAL							
	PANTOPRAZOLE SODIUM							
>A> AB	INGENUS PHARMS LLC	EQ 40MG BASE		A211368	001	Mar 01, 2019	Feb	NEWA

PENICILLAMINE

	CAPSULE;ORAL							
	CUPRIMINE							
	@ VALEANT PHARMS INTL	125MG		N019853	002		Jan	CAHN
	+!	250MG		N019853	001		Jan	CAHN

PERPHENAZINE

	TABLET;ORAL							
	PERPHENAZINE							
>A> AB	RISING PHARMS	2MG		A205056	001	Mar 01, 2019	Feb	NEWA
>A> AB		4MG		A205056	002	Mar 01, 2019	Feb	NEWA
>A> AB		8MG		A205056	003	Mar 01, 2019	Feb	NEWA
>A> AB		16MG		A205056	004	Mar 01, 2019	Feb	NEWA

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

AP	FRESENIUS KABI USA	10MG/ML (10MG/ML)	A210665	001	Jan 29, 2019	Jan NEWA
AP		50MG/5ML (10MG/ML)	A210666	001	Jan 30, 2019	Jan NEWA
AP		100MG/10ML (10MG/ML)	A210666	002	Jan 30, 2019	Jan NEWA
AP	SANDOZ INC	10MG/ML (10MG/ML)	A208905	001	Jan 31, 2019	Jan NEWA
AP		50MG/5ML (10MG/ML)	A208905	002	Jan 31, 2019	Jan NEWA
AP		100MG/10ML (10MG/ML)	A208905	003	Jan 31, 2019	Jan NEWA

SOLUTION/DROPS; OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

AT	AKORN INC	2.5%	N207926	001	Jan 15, 2015	Jan CTEC
AT		10%	N207926	002	Jan 15, 2015	Jan CTEC
AT	PARAGON BIOTECK	2.5%	N203510	001	Mar 21, 2013	Jan CTEC
AT		10%	N203510	002	Mar 21, 2013	Jan CTEC

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

>D>	AP	LUITPOLD	50MG/ML	A040781	001	Dec 04, 2007	Feb DISC
>A>		@	50MG/ML	A040781	001	Dec 04, 2007	Feb DISC

PHYTONADIONE

TABLET; ORAL

MEPHYTON

>A>	AB	BAUSCH	5MG	N010104	003		Feb CAHN
>D>	AB	VALEANT PHARMS INTL	5MG	N010104	003		Feb CAHN
	AB		5MG	N010104	003		Jan CAHN
		PHYTONADIONE					
>A>	AB	ZYDUS	5MG	A210189	001	Feb 20, 2019	Feb NEWA

PIMAVANSERIN TARTRATE

TABLET; ORAL

NUPLAZID

		+ @ ACADIA PHARMS INC	EQ 17MG BASE	N207318	001	Apr 29, 2016	Jan DISC
--	--	-----------------------	--------------	---------	-----	--------------	----------

PIROXICAM

CAPSULE; ORAL

PIROXICAM

		@ BRECKENRIDGE PHARM	10MG	A208991	001	Feb 21, 2018	Jan DISC
		@	20MG	A208991	002	Feb 21, 2018	Jan DISC
>A>	AB	CADILA	10MG	A205585	001	Jul 17, 2018	Feb CAHN
>A>	AB		20MG	A205585	002	Jul 17, 2018	Feb CAHN
>D>	AB	ZYDUS PHARMS USA INC	10MG	A205585	001	Jul 17, 2018	Feb CAHN
>D>	AB		20MG	A205585	002	Jul 17, 2018	Feb CAHN

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

>A>	AB	ZYDUS PHARMS USA INC	8MEQ	A208445	001	Mar 11, 2019	Feb NEWA
>A>	AB		10MEQ	A208445	002	Mar 11, 2019	Feb NEWA

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB2		PII	8MEQ	A206881	001	Jan 22, 2019	Jan NEWA
AB2			10MEQ	A206881	002	Jan 22, 2019	Jan NEWA

PREDNISONE

TABLET; ORAL

PREDNISONE

AB		SUN PHARM INDUSTRIES	5MG	A089247	002	Dec 04, 1985	Jan CMS1
AB			10MG	A089247	003	Dec 04, 1985	Jan CMS1

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

>A>	AP	NEXUS PHARMS	EQ 5MG BASE/ML	A204860	001	Feb 15, 2019	Feb NEWA
-----	----	--------------	----------------	---------	-----	--------------	----------

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION
MESTINON

>A>	AP	+	!	BAUSCH	5MG/ML	N009830	001		Feb	CAHN
>D>	AP	+	!	VALEANT PHARM INTL	5MG/ML	N009830	001		Feb	CAHN

SYRUP; ORAL
MESTINON

>A>	AA	+	!	BAUSCH	60MG/5ML	N015193	001		Feb	CFTG
>A>		+	!		60MG/5ML	N015193	001		Feb	CAHN
>D>		+	!	VALEANT PHARMS	60MG/5ML	N015193	001		Feb	CFTG
>D>		+	!		60MG/5ML	N015193	001		Feb	CAHN

PYRIDOSTIGMINE BROMIDE

>A>	AA			NOVITIUM PHARMA	60MG/5ML	A211694	001	Mar 08, 2019	Feb	NFTG
-----	----	--	--	-----------------	----------	---------	-----	--------------	-----	------

TABLET; ORAL
MESTINON

>A>	AB	+	!	BAUSCH	60MG	N009829	002		Feb	CAHN
>D>	AB	+	!	VALEANT PHARMS LLC	60MG	N009829	002		Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL
MESTINON

>A>	AB	+	!	BAUSCH	180MG	N011665	001		Feb	CAHN
>D>	AB	+	!	VALEANT PHARMS LLC	180MG	N011665	001		Feb	CAHN

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL
RABEPRAZOLE SODIUM

>D>	AB			BRECKENRIDGE PHARM	20MG	A204237	001	Nov 18, 2015	Feb	CAHN
>A>	AB			RUBICON	20MG	A204237	001	Nov 18, 2015	Feb	CAHN

RANITIDINE HYDROCHLORIDE

SYRUP; ORAL
RANITIDINE HYDROCHLORIDE

AA				TORRENT	EQ 15MG BASE/ML	A090102	001	May 26, 2009	Jan	CAHN
----	--	--	--	---------	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL
RANITIDINE HYDROCHLORIDE

>A>	AB			HERITAGE PHARMA	EQ 150MG BASE	A075165	001	Sep 30, 1998	Feb	CAHN
>A>	AB				EQ 300MG BASE	A075165	002	Sep 30, 1998	Feb	CAHN
>D>	AB			IVAX SUB TEVA PHARMS	EQ 150MG BASE	A075165	001	Sep 30, 1998	Feb	CAHN
>D>	AB				EQ 300MG BASE	A075165	002	Sep 30, 1998	Feb	CAHN
	AB			VKT PHARMA PVT LTD	EQ 150MG BASE	A211289	001	Jan 31, 2019	Jan	NEWA
	AB				EQ 300MG BASE	A211289	002	Jan 31, 2019	Jan	NEWA

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL
RANEXA

>D>		+		GILEAD	500MG	N021526	002	Jan 27, 2006	Feb	CTEC
>A>	AB				500MG	N021526	002	Jan 27, 2006	Feb	CTEC
>D>		+	!		1GM	N021526	001	Feb 12, 2007	Feb	CTEC
>A>	AB				1GM	N021526	001	Feb 12, 2007	Feb	CTEC

RANOLAZINE

>D>				@ LUPIN LTD	500MG	A201046	001	Jul 29, 2013	Feb	CMFD
>A>	AB				500MG	A201046	001	Jul 29, 2013	Feb	CMFD
>D>				@	1GM	A201046	002	Jul 29, 2013	Feb	CMFD
>A>	AB				1GM	A201046	002	Jul 29, 2013	Feb	CMFD

REPAGLINIDE

TABLET; ORAL
REPAGLINIDE

>D>	AB			MYLAN PHARMS INC	0.5MG	A090252	001	Aug 23, 2013	Feb	DISC
>A>				@	0.5MG	A090252	001	Aug 23, 2013	Feb	DISC

RIBAVIRIN

TABLET; ORAL
RIBAVIRIN

>A>	AB			BEXIMCO PHARMS USA	200MG	A202546	001	Aug 12, 2014	Feb	CAHN
>A>	AB				400MG	A202546	002	Aug 12, 2014	Feb	CAHN
>A>	AB				500MG	A202546	003	Aug 12, 2014	Feb	CAHN
>A>	AB				600MG	A202546	004	Aug 12, 2014	Feb	CAHN
>D>	AB			SANDOZ INC	200MG	A202546	001	Aug 12, 2014	Feb	CAHN
>D>	AB				400MG	A202546	002	Aug 12, 2014	Feb	CAHN
>D>	AB				500MG	A202546	003	Aug 12, 2014	Feb	CAHN
>D>	AB				600MG	A202546	004	Aug 12, 2014	Feb	CAHN

RISEDRONATE SODIUM

TABLET;ORAL

RISEDRONATE SODIUM

>A>	AB	HANGZHOU BINJIANG	35MG	A207516	001	Feb 15, 2019	Feb NEWA
		TABLET, DELAYED RELEASE;ORAL					
		RISEDRONATE SODIUM					
>D>	AB	ZYDUS PHARMS USA INC	35MG	A203822	001	Sep 11, 2018	Feb DISC
>A>		@	35MG	A203822	001	Sep 11, 2018	Feb DISC

RISPERIDONE

SOLUTION;ORAL

RISPERIDONE

AA		TORRENT	1MG/ML	A078909	001	Jul 29, 2009	Jan CAHN
----	--	---------	--------	---------	-----	--------------	----------

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

RIVASTIGMINE

>A>	AB	ZYDUS NOVELTECH INC	4.6MG/24HR	A206318	001	Mar 04, 2019	Feb NEWA
>A>	AB		9.5MG/24HR	A206318	002	Mar 04, 2019	Feb NEWA
>A>	AB		13.3MG/24HR	A206318	003	Mar 04, 2019	Feb NEWA

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

>A>	AB	CADILA	EQ 0.25MG BASE	A090411	001	Jun 01, 2009	Feb CAHN
>A>	AB		EQ 0.5MG BASE	A090411	002	Jun 01, 2009	Feb CAHN
>A>	AB		EQ 1MG BASE	A090411	003	Jun 01, 2009	Feb CAHN
>A>	AB		EQ 2MG BASE	A090411	004	Jun 01, 2009	Feb CAHN
>A>	AB		EQ 3MG BASE	A090411	005	Jun 01, 2009	Feb CAHN
>A>	AB		EQ 4MG BASE	A090411	006	Jun 01, 2009	Feb CAHN
>A>	AB		EQ 5MG BASE	A090411	007	Jun 01, 2009	Feb CAHN
>D>	AB	ZYDUS PHARMS USA INC	EQ 0.25MG BASE	A090411	001	Jun 01, 2009	Feb CAHN
>D>	AB		EQ 0.5MG BASE	A090411	002	Jun 01, 2009	Feb CAHN
>D>	AB		EQ 1MG BASE	A090411	003	Jun 01, 2009	Feb CAHN
>D>	AB		EQ 2MG BASE	A090411	004	Jun 01, 2009	Feb CAHN
>D>	AB		EQ 3MG BASE	A090411	005	Jun 01, 2009	Feb CAHN
>D>	AB		EQ 4MG BASE	A090411	006	Jun 01, 2009	Feb CAHN
>D>	AB		EQ 5MG BASE	A090411	007	Jun 01, 2009	Feb CAHN

ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSUVASTATIN CALCIUM

>A>	AB	ZYDUS PHARMS USA INC	5MG	A206513	001	Mar 01, 2019	Feb NEWA
>A>	AB		10MG	A206513	002	Mar 01, 2019	Feb NEWA
>A>	AB		20MG	A206513	003	Mar 01, 2019	Feb NEWA
>A>	AB		40MG	A206513	004	Mar 01, 2019	Feb NEWA

RUFINAMIDE

TABLET;ORAL

RUFINAMIDE

>D>	AB	MYLAN PHARMS INC	200MG	A205095	001	May 16, 2016	Feb DISC
>A>		@	200MG	A205095	001	May 16, 2016	Feb DISC
>D>	AB		400MG	A205095	002	May 16, 2016	Feb DISC
>A>		@	400MG	A205095	002	May 16, 2016	Feb DISC

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

>A>	AB	CADILA	EQ 25MG BASE	A077106	001	Feb 06, 2007	Feb CAHN
>A>	AB		EQ 50MG BASE	A077106	002	Feb 06, 2007	Feb CAHN
>A>	AB		EQ 100MG BASE	A077106	003	Feb 06, 2007	Feb CAHN
>D>	AB	ZYDUS PHARMS USA	EQ 25MG BASE	A077106	001	Feb 06, 2007	Feb CAHN
>D>	AB		EQ 50MG BASE	A077106	002	Feb 06, 2007	Feb CAHN
>D>	AB		EQ 100MG BASE	A077106	003	Feb 06, 2007	Feb CAHN

SEVELAMER HYDROCHLORIDE

TABLET;ORAL

RENAGEL

>D>		+	GENZYME	400MG	N021179	001	Jul 12, 2000	Feb CFTG
>A>	AB		+	400MG	N021179	001	Jul 12, 2000	Feb CFTG
>D>			+	800MG	N021179	002	Jul 12, 2000	Feb CFTG

TABLET;ORAL
 RENAGEL
 >A> AB +! 800MG N021179 002 Jul 12, 2000 Feb CFTG
 >A> SEVELAMER HYDROCHLORIDE
 >A> AB GLENMARK PHARMS LTD 400MG A204724 001 Feb 08, 2019 Feb NFTG
 >A> AB 800MG A204724 002 Feb 08, 2019 Feb NFTG

SIROLIMUS

SOLUTION;ORAL
 RAPAMUNE
 AA +! PF PRISM CV 1MG/ML N021083 001 Sep 15, 1999 Jan CFTG
 SIROLIMUS
 AA NOVITIUM PHARMA 1MG/ML A211040 001 Jan 28, 2019 Jan NFTG

SODIUM CHLORIDE

INJECTABLE;INJECTION
 SODIUM CHLORIDE 3% IN PLASTIC CONTAINER
 >A> AP FRESENIUS KABI USA 3GM/100ML A209476 001 Mar 13, 2019 Feb NEWA

SODIUM CHROMATE CR-51

INJECTABLE;INJECTION
 SODIUM CHROMATE CR 51
 @ CURIUM 100uCi/ML N016708 001 Jan CAHN

SODIUM IODIDE I-131

CAPSULE;ORAL
 SODIUM IODIDE I 131
 @ CURIUM 0.8-100mCi N016515 002 Jan CAHN
 + @ 0.8-100mCi N016517 001 Jan CAHN
 @ 15-100uCi N016517 002 Jan CAHN
 SOLUTION;ORAL
 SODIUM IODIDE I 131
 + @ CURIUM 3.5-150mCi/VIAL N016515 001 Jan CAHN

SODIUM PHENYLBUTYRATE

POWDER;ORAL
 BUPHENYL
 >D> AB +! HORIZON PHARMA INC 3GM/TEASPOONFUL N020573 001 Apr 30, 1996 Feb CAHN
 >A> AB +! HORIZON THERAP 3GM/TEASPOONFUL N020573 001 Apr 30, 1996 Feb CAHN
 TABLET;ORAL
 BUPHENYL
 >D> AB +! HORIZON PHARMA INC 500MG N020572 001 May 13, 1996 Feb CAHN
 >A> AB +! HORIZON THERAP 500MG N020572 001 May 13, 1996 Feb CAHN

STRONTIUM CHLORIDE SR-89

INJECTABLE;INJECTION
 METASTRON
 AP +! Q BIOMED 1mCi/ML N020134 001 Jun 18, 1993 Jan CAHN

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION
 SUCCINYLCHOLINE CHLORIDE
 AP AMRING PHARMS 20MG/ML A210231 001 Jun 04, 2018 Jan CAHN

SUMATRIPTAN

SPRAY;NASAL
 TOSYMRA
 +! DR REDDYS LABS LTD 10MG/SPRAY N210884 001 Jan 25, 2019 Jan NEWA

TACROLIMUS

OINTMENT;TOPICAL
 TACROLIMUS
 AB ACCORD HLTHCARE 0.03% A211688 001 Jan 31, 2019 Jan NEWA
 AB 0.1% A211688 002 Jan 31, 2019 Jan NEWA

TADALAFIL

TABLET;ORAL
 ALYQ
 AB2 TEVA PHARMS USA 20MG A209942 001 Feb 05, 2019 Jan NEWA
 TADALAFIL
 AB2 AJANTA PHARMA LTD 20MG A210392 001 Feb 05, 2019 Jan NEWA

TABLET;ORAL

TADALAFIL

AB2	AUROBINDO PHARMA LTD	20MG	A206286	001	Feb 05, 2019	Jan NEWA
AB2	CIPLA	20MG	A210255	001	Feb 05, 2019	Jan NEWA
AB2	DR REDDYS LABS LTD	20MG	A210145	001	Feb 05, 2019	Jan NEWA
AB2	HETERO LABS LTD III	20MG	A209907	001	Feb 05, 2019	Jan NEWA
AB2	LUPIN LTD	20MG	A210572	001	Feb 05, 2019	Jan NEWA

TAZAROTENE

CREAM;TOPICAL

TAZAROTENE

AB	FOUGERA PHARMS INC	1%	A211175	001	Jan 28, 2019	Jan NEWA
----	--------------------	----	---------	-----	--------------	----------

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE;INJECTION

TECHNESCAN MAG3

+!	CURIUM	N/A	N019882	001	Jun 15, 1990	Jan CAHN
----	--------	-----	---------	-----	--------------	----------

TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE;INJECTION

TECHNESCAN

+!	CURIUM	N/A	N018321	001		Jan CAHN
----	--------	-----	---------	-----	--	----------

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE;INJECTION

TECHNESCAN PYP KIT

AP	CURIUM	N/A	N017538	001		Jan CAHN
----	--------	-----	---------	-----	--	----------

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE;INJECTION

ULTRATAG

+!	CURIUM	N/A	N019981	001	Jun 10, 1991	Jan CAHN
----	--------	-----	---------	-----	--------------	----------

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION;INTRAVENOUS

ULTRA-TECHNEKOW FM

+!	CURIUM	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014	Jan CAHN
@		0.25-3 CI/GENERATOR	N017243	002		Jan CAHN

SOLUTION;INTRAVENOUS, ORAL

>D>		TECHNETIUM TC 99M GENERATOR				
>D>	+!	GE HEALTHCARE	68-2703mCi/GENERATOR	N017693	002	Dec 13, 2013 Feb DISC
>A>	+ @		68-2703mCi/GENERATOR	N017693	002	Dec 13, 2013 Feb DISC

TELMISARTAN

TABLET;ORAL

TELMISARTAN

>A>	AB	CIPLA	20MG	A078710	001	Jan 08, 2014 Feb CAHN
>A>		@	40MG	A078710	002	Jan 08, 2014 Feb CAHN
>A>		@	80MG	A078710	003	Jan 08, 2014 Feb CAHN
>A>	AB	HISUN PHARM HANGZHOU	20MG	A207843	001	Feb 19, 2019 Feb NEWA
>A>	AB		40MG	A207843	002	Feb 19, 2019 Feb NEWA
>A>	AB		80MG	A207843	003	Feb 19, 2019 Feb NEWA
>D>	AB	WATSON LABS	20MG	A078710	001	Jan 08, 2014 Feb CAHN
>D>		@	40MG	A078710	002	Jan 08, 2014 Feb CAHN
>D>	AB		80MG	A078710	003	Jan 08, 2014 Feb CAHN
>D>	AB		80MG	A078710	003	Jan 08, 2014 Feb DISC
>A>		@	80MG	A078710	003	Jan 08, 2014 Feb DISC

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

@	APOTEX INC	5MG	A204159	001	Jul 05, 2018	Jan DISC
@		20MG	A204159	002	Jul 05, 2018	Jan DISC
@		100MG	A204159	003	Jul 05, 2018	Jan DISC
@		140MG	A204159	004	Jul 05, 2018	Jan DISC
@		180MG	A204159	005	Jul 05, 2018	Jan DISC
@		250MG	A204159	006	Jul 05, 2018	Jan DISC

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

TENOFOVIR DISOPROXIL FUMARATE

@ APOTEX INC 300MG A206481 001 Jul 26, 2018 Jan DISC

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

>A> @ BEXIMCO PHARMS USA EQ 1MG BASE A075667 001 Jul 28, 2000 Feb CAHN
 >A> @ EQ 2MG BASE A075667 002 Jul 28, 2000 Feb CAHN
 >A> @ EQ 5MG BASE A075667 003 Jul 28, 2000 Feb CAHN
 >A> @ EQ 10MG BASE A075667 004 Jul 28, 2000 Feb CAHN
 >D> @ SANDOZ EQ 1MG BASE A075667 001 Jul 28, 2000 Feb CAHN
 >D> @ EQ 2MG BASE A075667 002 Jul 28, 2000 Feb CAHN
 >D> @ EQ 5MG BASE A075667 003 Jul 28, 2000 Feb CAHN
 >D> @ EQ 10MG BASE A075667 004 Jul 28, 2000 Feb CAHN

TERIFLUNOMIDE

TABLET;ORAL

TERIFLUNOMIDE

>D> AB AMNEAL PHARMS CO 7MG A209613 001 Sep 28, 2018 Feb DISC
 >A> @ 7MG A209613 001 Sep 28, 2018 Feb DISC
 >D> AB 14MG A209613 002 Sep 28, 2018 Feb DISC
 >A> @ 14MG A209613 002 Sep 28, 2018 Feb DISC
 @ APOTEX INC 7MG A209601 001 Nov 02, 2018 Jan DISC
 @ 14MG A209601 002 Nov 02, 2018 Jan DISC
 >D> AB AUROBINDO PHARMA LTD 7MG A209638 001 Oct 26, 2018 Feb DISC
 >A> @ 7MG A209638 001 Oct 26, 2018 Feb DISC
 >D> AB 14MG A209638 002 Oct 26, 2018 Feb DISC
 >A> @ 14MG A209638 002 Oct 26, 2018 Feb DISC
 >D> AB WATSON LABS TEVA 7MG A209549 001 Jul 27, 2018 Feb DISC
 >A> @ 7MG A209549 001 Jul 27, 2018 Feb DISC
 >D> AB 14MG A209549 002 Jul 27, 2018 Feb DISC
 >A> @ 14MG A209549 002 Jul 27, 2018 Feb DISC

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

TESTOSTERONE CYPIONATE

>D> AO LUITPOLD 200MG/ML A207742 001 Jun 16, 2017 Feb DISC
 >A> @ 200MG/ML A207742 001 Jun 16, 2017 Feb DISC

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

>D> AB LUPIN LTD 12.5MG A210544 001 Apr 20, 2018 Feb DISC
 >A> @ 12.5MG A210544 001 Apr 20, 2018 Feb DISC
 >D> AB 25MG A210544 002 Apr 20, 2018 Feb DISC
 >A> @ 25MG A210544 002 Apr 20, 2018 Feb DISC

THALLOUS CHLORIDE TL-201

INJECTABLE;INJECTION

THALLOUS CHLORIDE TL 201

AP +! CURIUM 1mCi/ML N018150 001 Jan CAHN

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL

THEOPHYLLINE

>A> AB ! HERITAGE PHARMA 100MG A089807 001 Apr 30, 1990 Feb CAHN
 >A> AB ! 200MG A089808 001 Apr 30, 1990 Feb CAHN
 >A> AB 300MG A089763 001 Apr 30, 1990 Feb CAHN
 >A> @ 450MG A081236 001 Nov 09, 1992 Feb CAHN
 >D> AB ! PLIVA 100MG A089807 001 Apr 30, 1990 Feb CAHN
 >D> AB ! 200MG A089808 001 Apr 30, 1990 Feb CAHN
 >D> AB 300MG A089763 001 Apr 30, 1990 Feb CAHN
 >D> @ TEVA PHARMS 450MG A081236 001 Nov 09, 1992 Feb CAHN

TICAGRELOR

TABLET; ORAL
TICAGRELOR

AB	AMNEAL PHARMS CO	90MG	A208531	001	Jan 23, 2019	Jan	NEWA
AB	HISUN PHARM HANGZHOU	90MG	A208575	001	Jan 23, 2019	Jan	NEWA
>D>	AB	WATSON LABS INC	60MG	A208390	001	Sep 04, 2018	Feb DISC
>A>	@	60MG	A208390	001	Sep 04, 2018	Feb	DISC
>D>	AB	90MG	A208390	002	Sep 04, 2018	Feb	DISC
>A>	@	90MG	A208390	002	Sep 04, 2018	Feb	DISC

TIGECYCLINE

POWDER; INTRAVENOUS
TIGECYCLINE

>D>	AP	AMNEAL PHARMS LLC	50MG/VIAL	N211158	001	Aug 02, 2018	Feb DISC
>A>	@	50MG/VIAL	N211158	001	Aug 02, 2018	Feb	DISC

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
TIMOPTIC

AT	+	VALEANT PHARMS INTL	EQ 0.25% BASE	N018086	001		Jan CAHN
AT1	+		EQ 0.5% BASE	N018086	002		Jan CAHN
		TIMOPTIC IN OCUDOSE					
	+	VALEANT PHARMS INTL	EQ 0.25% BASE	N019463	001	Nov 05, 1986	Jan CAHN
	+		EQ 0.5% BASE	N019463	002	Nov 05, 1986	Jan CAHN

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL
TIZANIDINE HYDROCHLORIDE

>A>	AB	RICONPHARMA LLC	EQ 2MG BASE	A210267	001	Mar 12, 2019	Feb NEWA
>A>	AB		EQ 4MG BASE	A210267	002	Mar 12, 2019	Feb NEWA
>A>	AB		EQ 6MG BASE	A210267	003	Mar 12, 2019	Feb NEWA

TABLET; ORAL
TIZANIDINE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 2MG BASE	A211798	001	Jan 25, 2019	Jan	NEWA
AB		EQ 4MG BASE	A211798	002	Jan 25, 2019	Jan	NEWA

TOBRAMYCIN

SOLUTION; INHALATION
TOBRAMYCIN

@	DR REDDYS LABS SA	300MG/5ML	A207080	001	Jul 09, 2018	Jan	DISC
---	-------------------	-----------	---------	-----	--------------	-----	------

TOPIRAMATE

CAPSULE, EXTENDED RELEASE; ORAL
QUDEXY XR

>D>	+	UPSHER SMITH LABS	25MG	N205122	001	Mar 11, 2014	Feb CTEC
>A>	BC	+	25MG	N205122	001	Mar 11, 2014	Feb CTEC
>D>	+		50MG	N205122	002	Mar 11, 2014	Feb CTEC
>A>	BC	+	50MG	N205122	002	Mar 11, 2014	Feb CTEC
>D>	+		100MG	N205122	003	Mar 11, 2014	Feb CTEC
>A>	BC	+	100MG	N205122	003	Mar 11, 2014	Feb CTEC
>D>	+		200MG	N205122	005	Mar 11, 2014	Feb CTEC
>A>	BC	+	200MG	N205122	005	Mar 11, 2014	Feb CTEC

TRANEXAMIC ACID

INJECTABLE; INJECTION
TRANEXAMIC ACID

>A>	AP	ACIC PHARMS	100MG/ML	A209326	001	Feb 22, 2019	Feb NEWA
-----	----	-------------	----------	---------	-----	--------------	----------

TREPROSTINIL DIOLAMINE

TABLET, EXTENDED RELEASE; ORAL
ORENITRAM

>D>	+	UNITED THERAP	EQ 1MG BASE	N203496	003	Dec 20, 2013	Feb CHRS
>A>	+		EQ 1MG BASE	N203496	003	Dec 20, 2013	Feb CHRS
>D>	+		EQ 2.5MG BASE	N203496	004	Dec 20, 2013	Feb CHRS
>A>	+		EQ 2.5MG BASE	N203496	004	Dec 20, 2013	Feb CHRS

TRETINOIN

CREAM; TOPICAL
TRETINOIN

AB1	TARO PHARMS	0.05%	A211644	001	Jan 25, 2019	Jan NEWA
AB		0.1%	A211645	001	Jan 22, 2019	Jan NEWA

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE

AT	STRIDES PHARMA	0.025%	A210346	001	Feb 11, 2019	Jan NEWA
AT		0.1%	A210346	002	Feb 11, 2019	Jan NEWA
AT		0.5%	A210346	003	Feb 11, 2019	Jan NEWA

>A> TRICLABENDAZOLE

TABLET; ORAL
EGATEN

>A>	+!	NOVARTIS PHARMS CORP	250MG	N208711	001	Feb 13, 2019	Feb NEWA
-----	----	----------------------	-------	---------	-----	--------------	----------

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL
TRIENTINE HYDROCHLORIDE

>A>	AB	AMNEAL PHARMS LLC	250MG	A210619	001	Feb 08, 2019	Feb NEWA
-----	----	-------------------	-------	---------	-----	--------------	----------

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE; ORAL
TRIMETHOBENZAMIDE HYDROCHLORIDE

>D>	AB	GAVIS PHARMS	300MG	A076546	001	Aug 20, 2003	Feb CAHN
>A>	AB	LUPIN	300MG	A076546	001	Aug 20, 2003	Feb CAHN

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

>D>	AP	LUITPOLD	100MG/ML	A091330	001	Mar 08, 2011	Feb DISC
>A>		@	100MG/ML	A091330	001	Mar 08, 2011	Feb DISC
>D>		TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE					
>D>	AP	LUITPOLD	100MG/ML	A091329	001	Mar 08, 2011	Feb DISC
>A>		@	100MG/ML	A091329	001	Mar 08, 2011	Feb DISC

VALSARTAN

TABLET; ORAL
VALSARTAN

>A>	AB	ALKEM LABS LTD	40MG	A205536	001	Mar 12, 2019	Feb NEWA
>A>	AB		80MG	A205536	002	Mar 12, 2019	Feb NEWA
>A>	AB		160MG	A205536	003	Mar 12, 2019	Feb NEWA
>A>	AB		320MG	A205536	004	Mar 12, 2019	Feb NEWA

VANCOMYCIN HYDROCHLORIDE

SOLUTION; INTRAVENOUS
VANCOMYCIN HYDROCHLORIDE

>A>	+!	XELLIA PHARMS APS	EQ 500MG BASE/100ML	N211962	001	Feb 15, 2019	Feb NEWA
>A>	+!		EQ 1GM BASE/200ML	N211962	002	Feb 15, 2019	Feb NEWA
>A>	+!		EQ 1.5GM BASE/300ML	N211962	003	Feb 15, 2019	Feb NEWA
>A>	+!		EQ 2GM BASE/400ML	N211962	004	Feb 15, 2019	Feb NEWA

VORICONAZOLE

POWDER; IV (INFUSION)
VORICONAZOLE

>D>		XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	Feb CTEC
>A>	AP		200MG/VIAL	N208562	001	Mar 09, 2017	Feb CTEC

TABLET; ORAL
VORICONAZOLE

>A>	AB	APPCO PHARMA LLC	50MG	A206762	001	May 24, 2016	Feb CAHN
>A>	AB		200MG	A206762	002	May 24, 2016	Feb CAHN
>D>	AB	RISING PHARMS	50MG	A206762	001	May 24, 2016	Feb CAHN
>D>	AB		200MG	A206762	002	May 24, 2016	Feb CAHN

ZIDOVUDINE

INJECTABLE; INJECTION
ZIDOVUDINE

>D>	AP	LUITPOLD	10MG/ML	A091457	001	May 06, 2010	Feb DISC
>A>		@	10MG/ML	A091457	001	May 06, 2010	Feb DISC

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

ZIPRASIDONE HYDROCHLORIDE

>A>	AB	CADILA	EQ 20MG BASE	A208988	001	Aug 22, 2017	Feb CAHN
>A>	AB		EQ 40MG BASE	A208988	002	Aug 22, 2017	Feb CAHN
>A>	AB		EQ 60MG BASE	A208988	003	Aug 22, 2017	Feb CAHN
>A>	AB		EQ 80MG BASE	A208988	004	Aug 22, 2017	Feb CAHN
>D>	AB	ZYDUS PHARMS USA INC	EQ 20MG BASE	A208988	001	Aug 22, 2017	Feb CAHN
>D>	AB		EQ 40MG BASE	A208988	002	Aug 22, 2017	Feb CAHN
>D>	AB		EQ 60MG BASE	A208988	003	Aug 22, 2017	Feb CAHN
>D>	AB		EQ 80MG BASE	A208988	004	Aug 22, 2017	Feb CAHN

ZOLPIDEM TARTRATE

SPRAY, METERED;ORAL

ZOLPIMIST

>A>	+!	AYTU	5MG/SPRAY	N022196	001	Dec 19, 2008	Feb CAHN
>D>	+!	MAGNA PHARMS	5MG/SPRAY	N022196	001	Dec 19, 2008	Feb CAHN

ACETAMINOPHEN

SUPPOSITORY;RECTAL
ACEPHEN

>A>	ACP NIMBLE	120MG	N018060	001		Feb	CAHN
>A>	@	325MG	N018060	003	Dec 18, 1986	Feb	CAHN
>A>	@	650MG	N018060	002		Feb	CAHN
>D>	G AND W LABS	120MG	N018060	001		Feb	CAHN
>D>	@	325MG	N018060	003	Dec 18, 1986	Feb	CAHN
>D>	@	650MG	N018060	002		Feb	CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>A>	HETERO LABS LTD III	5MG/5ML	A210622	001	Mar 13, 2019	Feb	NEWA
	TORRENT	5MG/5ML	A090474	002	Mar 30, 2009	Jan	CAHN
	CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF						
	TORRENT	5MG/5ML	A090474	001	Mar 30, 2009	Jan	CAHN

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE;ORAL

CHLOR-TRIMETON

>D>	@ BAYER HEALTHCARE LLC	8MG	N007638	001		Feb	CRLD
>A>	+ @	8MG	N007638	001		Feb	CRLD
	+ @	12MG	N007638	002		Jan	DISC
	CHLORPHENIRAMINE MALEATE						
	! AVANTHI INC	12MG	A040829	001	May 13, 2009	Jan	CHRS

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

AUROBINDO PHARMA LTD 25MG;EQ 200MG FREE ACID AND
POTASSIUM SALT

A210676 001 Feb 14, 2019 Jan NEWA

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

ACTAVIS ELIZABETH 25MG;220MG

A207597 001 Jan 25, 2019 Jan NEWA

ESOMEPRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

>A>	ACTAVIS ELIZABETH	EQ 20MG BASE	A209202	001	Mar 05, 2019	Feb	NEWA
-----	-------------------	--------------	---------	-----	--------------	-----	------

IBUPROFEN

SUSPENSION;ORAL

IBUPROFEN

>D>	GUARDIAN DRUG	100MG/5ML	A210149	001	Aug 17, 2018	Feb	DISC
>A>	@	100MG/5ML	A210149	001	Aug 17, 2018	Feb	DISC

KETOCONAZOLE

SHAMPOO;TOPICAL

NIZORAL A-D

+!	KRAMER	1%	N020310	001	Oct 10, 1997	Jan	CAHN
----	--------	----	---------	-----	--------------	-----	------

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

KETOTIFEN FUMARATE

>D>	!	ALCON PHARMS LTD	EQ 0.025% BASE	A077200	001	Sep 02, 2008	Feb	CTNA
>A>		ZADITOR						
>A>	!	ALCON PHARMS LTD	EQ 0.025% BASE	A077200	001	Sep 02, 2008	Feb	CTNA

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

@	APOTEX INC	1.5MG	A205329	001	Sep 18, 2018	Jan	DISC
---	------------	-------	---------	-----	--------------	-----	------

LORATADINETABLET;ORAL
LORATADINE

>A>	NEWGEN PHARMS LLC	10MG	A207569	001	Mar 12, 2019	Feb	NEWA
-----	-------------------	------	---------	-----	--------------	-----	------

NICOTINE POLACRILEXTROCHE/LOZENGE;ORAL
NICOTINE POLACRILEX

>A>	PLD ACQUISITIONS	EQ 2MG BASE	A207868	001	Feb 07, 2019	Feb	NEWA
>A>		EQ 4MG BASE	A207868	002	Feb 07, 2019	Feb	NEWA
>D>	WATSON LABS INC	EQ 2MG BASE	A209206	001	Jun 26, 2018	Feb	DISC
>A>	@	EQ 2MG BASE	A209206	001	Jun 26, 2018	Feb	DISC
>D>		EQ 4MG BASE	A209206	002	Jun 26, 2018	Feb	DISC
>A>	@	EQ 4MG BASE	A209206	002	Jun 26, 2018	Feb	DISC
>D>	WATSON LABS TEVA	EQ 2MG BASE	A209519	001	Jul 02, 2018	Feb	DISC
>A>	@	EQ 2MG BASE	A209519	001	Jul 02, 2018	Feb	DISC
>D>		EQ 4MG BASE	A209519	002	Jul 02, 2018	Feb	DISC
>A>	@	EQ 4MG BASE	A209519	002	Jul 02, 2018	Feb	DISC

OMEPRAZOLETABLET, DELAYED RELEASE;ORAL
OMEPRAZOLE

	APOTEX INC	20MG	A210070	001	Feb 11, 2019	Jan	NEWA
--	------------	------	---------	-----	--------------	-----	------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 02 FEBRUARY 2019

NO FEBRUARY 2019 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO FEBRUARY 2019 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABIRATERONE ACETATE - ABIRATERONE ACETATE</u>						
A 208327	001				PC	Apr 29, 2019
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259	001	10167291	Jul 01, 2036	DP U-2145		
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653	002	8461137	Feb 22, 2031	DS DP		
		8748413	Jul 10, 2030	DS DP		
		8828978	Jul 01, 2030	DP		
		9132125	Jul 01, 2030	DS DP	U-2249	
		9549923	Jul 01, 2030	DS DP		
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653	003	8461137	Feb 22, 2031	DS DP		
		8748413	Jul 10, 2030	DS DP		
		8828978	Jul 01, 2030	DP		
		9132125	Jul 01, 2030	DS DP	U-2249	
		9549923	Jul 01, 2030	DS DP		
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636	001	10124131	May 18, 2031	DP		
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636	002	10022510	May 18, 2031	DP		
		10124131	May 18, 2031	DP		
		6701917	Jun 23, 2021	DP		
		6718972	Jun 23, 2021	DP		
		6748947	Jun 23, 2021	DP		
		6871646	Jun 23, 2021	DP		
		7540282	May 06, 2023	DP		
		8006690	Jun 23, 2021	DP		
		8651103	Mar 26, 2028	DP		
		8978966	Jan 13, 2032	DP		
		9216260	Jun 28, 2031	DP		
		9463288	May 19, 2025	DP		
		9731087	May 18, 2031	DP		
		9782550	Aug 28, 2035	DP		
		9782551	Aug 28, 2035	DP		
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203	001	>A> 10183012	Nov 26, 2028	U-2104		
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203	002	>A> 10183012	Nov 26, 2028	U-2104		
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905	001	10130580	Apr 19, 2024	DP		
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905	002	10130580	Apr 19, 2024	DP		
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905	003	10130580	Apr 19, 2024	DP		
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905	004	10130580	Apr 19, 2024	DP		
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813	001	>A> 10188811	Oct 21, 2031	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BECLOMETHASONE DIPROPIONATE - ONASL</u>						
N 202813 002	>A> 10188811	Oct 21, 2031	DP			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE</u>						
A 205128 001				>A> PC		Aug 18, 2019
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	>A> 10220049	Jun 03, 2029	DP U-916			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	>A> 10220049	Jun 03, 2029	DP U-916			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	10179137	Aug 31, 2030	DP U-1858			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001	9012462	Jul 31, 2030	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	9012462	Jul 31, 2030	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 003	9012462	Jul 31, 2030	DS			
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708 001	>A> 10201517	Jun 13, 2031	DP			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001	>A> 10198218	Jun 06, 2031	U-2489			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002	>A> 10198218	Jun 06, 2031	U-2489			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	10034873	Jul 18, 2031	U-2488		>A> I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		>A> ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	10034873	Jul 18, 2031	U-2488		>A> I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		>A> ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	10034873	Jul 18, 2031	U-2488		>A> I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		>A> ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	>A> 10213442	Feb 02, 2027	DP			
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	>A> 9907751	Nov 22, 2036	DP			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	>A> 10166184	Oct 15, 2032	DP U-2341			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DALFAMPRIDINE - DALFAMPRIDINE</u>						
A 206863	001				PC	Mar 09, 2019
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293	001				>A> M-238	Feb 22, 2022
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293	002				>A> M-238	Feb 22, 2022
<u>DASATINIB - SPRYCEL</u>						
N 021986	001				>A> ODE-225 >A> PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986	002				>A> ODE-225 >A> PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986	003				>A> ODE-225 >A> PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986	004				>A> ODE-225 >A> PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986	005				>A> ODE-225 >A> PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986	006				>A> ODE-225 >A> PED	Dec 21, 2025 Jun 21, 2026
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030	002	7049328	Jun 28, 2021	U-735		
		8703156	Oct 29, 2029	DP U-735		
<u>DEXAMETHASONE - DEXTENZA</u>						
N 208742	001	8409606	May 14, 2030	DP	NP	Nov 30, 2021
		8563027	Feb 12, 2030	U-2487		
		9254267	Sep 11, 2024	DP		
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912	001	10159683	May 23, 2034	DP		
<u>DOXYCYCLINE - ORACEA</u>						
N 050805	001	>A> 10058564	Apr 05, 2022	U-1063		
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291	001	>A> 7160870	Nov 20, 2022	DS DP U-1306		
		>A> 7160870	Nov 20, 2022	DS DP U-2451		
		>A> 7160870*PED	May 20, 2023			
		>A> 7332481	May 24, 2021	U-1306		
		>A> 7332481	May 24, 2021	U-2451		
		>A> 7332481*PED	Nov 24, 2021			
		>A> 7452874	May 24, 2021	DS DP		
		>A> 7452874*PED	Nov 24, 2021			
		>A> 7473686	May 24, 2021	DS DP U-1306		
		>A> 7473686	May 24, 2021	DS DP U-2451		
		>A> 7473686*PED	Nov 24, 2021			
		>A> 7547719	Jul 13, 2025	DS DP U-1306		
		>A> 7547719	Jul 13, 2025	DS DP U-1575		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	>A> 7547719	Jul 13, 2025	DS DP U-2451			
	>A> 7547719	Jul 13, 2025	DS DP U-2452			
	>A> 7547719*PED	Jan 13, 2026				
	>A> 7790704	May 24, 2021			U-1306	
	>A> 7790704	May 24, 2021			U-2451	
	>A> 7790704*PED	Nov 24, 2021				
	>A> 7795293	May 21, 2023			U-1306	
	>A> 7795293	May 21, 2023			U-2451	
	>A> 7795293*PED	Nov 21, 2023				
	>A> 8828430	Aug 01, 2027	DP U-1306			
	>A> 8828430	Aug 01, 2027	DP U-2451			
	>A> 8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-2451			
	>A> 7160870*PED	May 20, 2023				
	>A> 7332481	May 24, 2021			U-1306	
	>A> 7332481	May 24, 2021			U-2451	
	>A> 7332481*PED	Nov 24, 2021				
	>A> 7452874	May 24, 2021	DS DP			
	>A> 7452874*PED	Nov 24, 2021				
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7473686	May 24, 2021	DS DP U-2451			
	>A> 7473686*PED	Nov 24, 2021				
	>A> 7790704	May 24, 2021			U-1306	
	>A> 7790704	May 24, 2021			U-2451	
	>A> 7790704*PED	Nov 24, 2021				
	>A> 8828430	Aug 01, 2027	DP U-1306			
	>A> 8828430	Aug 01, 2027	DP U-2451			
	>A> 8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-2451			
	>A> 7160870*PED	May 20, 2023				
	>A> 7332481	May 24, 2021			U-1306	
	>A> 7332481	May 24, 2021			U-2451	
	>A> 7332481*PED	Nov 24, 2021				
	>A> 7452874	May 24, 2021	DS DP			
	>A> 7452874*PED	Nov 24, 2021				
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7473686	May 24, 2021	DS DP U-2451			
	>A> 7473686*PED	Nov 24, 2021				
	>A> 7790704	May 24, 2021			U-1306	
	>A> 7790704	May 24, 2021			U-2451	
	>A> 7790704*PED	Nov 24, 2021				
	>A> 8828430	Aug 01, 2027	DP U-1306			
	>A> 8828430	Aug 01, 2027	DP U-2451			
	>A> 8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-2451			
	>A> 7160870*PED	May 20, 2023				
	>A> 7332481	May 24, 2021			U-1306	
	>A> 7332481	May 24, 2021			U-2451	
	>A> 7332481*PED	Nov 24, 2021				
	>A> 7452874	May 24, 2021	DS DP			
	>A> 7452874*PED	Nov 24, 2021				
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7473686	May 24, 2021	DS DP U-2451			
	>A> 7473686*PED	Nov 24, 2021				
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-1575			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	>A> 7547719	Jul 13, 2025	DS DP U-2451			
	>A> 7547719	Jul 13, 2025	DS DP U-2452			
	>A> 7547719*PED	Jan 13, 2026				
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-2451			
	>A> 7790704*PED	Nov 24, 2021				
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-2451			
	>A> 7795293*PED	Nov 21, 2023				
	>A> 8828430	Aug 01, 2027	DP U-1306			
	>A> 8828430	Aug 01, 2027	DP U-2451			
	>A> 8828430*PED	Feb 01, 2028				
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	>A> 10188632	Mar 14, 2033	DP			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	>A> 10188632	Mar 14, 2033	DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	>A> 5753706	Feb 03, 2020	DP U-1577		I-790	Nov 06, 2020
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 208551 001	7816404	Apr 17, 2029	U-1656			
	7857977	Sep 08, 2027	U-1656			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	>A> 10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	>A> 10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	>A> 10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	10179216	Jul 08, 2033	DP U-2133			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	>A> 10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	>A> 10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	>A> 10195375	Feb 14, 2031	DP			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	>A> 10208073	May 23, 2032	U-2301			
<u>GILTERITINIB FUMARATE - XOSPATA</u>						
N 211349 001					NCE	Nov 28, 2023
<u>GLYCEROL PHENYL BUTYRATE - RAVICTI</u>						
N 203284 001	>A> 10183002	Sep 22, 2030	U-1816			
	>A> 10183003	Sep 22, 2030	U-1816			
	>A> 10183004	Sep 22, 2030	U-1816			
	>A> 10183005	Sep 22, 2030	U-1816			
	>A> 10183006	Sep 22, 2030	U-1816			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCORTISONE VALERATE - HYDROCORTISONE VALERATE</u>						
A 211750 001					CGT	Jul 16, 2019
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001					M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002					M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001					M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002					M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003					M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004					M-236	Jan 25, 2022
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG PENFILL</u>						
N 020986 002	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	>A> 7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	>A> 7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	8579869	Jun 30, 2023	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001	>A> 9011391	Mar 26, 2024		U-1923		
	>A> 9011391	Mar 26, 2024		U-2496		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	>A> 10201672	Aug 02, 2030	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	>A> 10201672	Aug 02, 2030	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	>A> 10201672	Aug 02, 2030	DP			
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 001	>A> 7361649	Feb 22, 2026	DS DP U-1694			
	>A> 7361650	Feb 22, 2026	DS DP U-1694			
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 002	>A> 7361649	Feb 22, 2026	DS DP U-1694			
	>A> 7361650	Feb 22, 2026	DS DP U-1694			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	>A> 10206939	Mar 13, 2034	U-1631			
<u>LAROTRECTINIB - VITRAKVI</u>						
N 210861 001					NCE	Nov 26, 2023
<u>LAROTRECTINIB - VITRAKVI</u>						
N 210861 002					NCE	Nov 26, 2023
<u>LAROTRECTINIB - VITRAKVI</u>						
N 211710 001					NCE	Nov 26, 2023
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	>A> 7189740	Apr 11, 2023	U-1982			
	>A> 7468363	Oct 07, 2023	U-1983			
	>A> 7968569	Oct 07, 2023	U-1984			
	>A> 8404717	Apr 11, 2023	U-1982			
	>A> 8530498	May 15, 2023	U-1984			
	>A> 8648095	May 15, 2023	U-1984			
	>A> 8741929	Mar 08, 2028	U-1983			
	>A> 9056120	Apr 11, 2023	U-1982			
	>A> 9101621	May 15, 2023	U-1985			
	>A> 9101622	May 15, 2023	U-1986			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	>A> 7189740	Apr 11, 2023	U-1982			
	>A> 7468363	Oct 07, 2023	U-1983			
	>A> 7968569	Oct 07, 2023	U-1984			
	>A> 8404717	Apr 11, 2023	U-1982			
	>A> 8530498	May 15, 2023	U-1984			
	>A> 8648095	May 15, 2023	U-1984			
	>A> 8741929	Mar 08, 2028	U-1983			
	>A> 9056120	Apr 11, 2023	U-1982			
	>A> 9101621	May 15, 2023	U-1985			
	>A> 9101622	May 15, 2023	U-1986			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	>A> 7189740	Apr 11, 2023	U-1982			
	>A> 7468363	Oct 07, 2023	U-1983			
	>A> 7968569	Oct 07, 2023	U-1984			
	>A> 8404717	Apr 11, 2023	U-1982			
	>A> 8530498	May 15, 2023	U-1984			
	>A> 8648095	May 15, 2023	U-1984			
	>A> 8741929	Mar 08, 2028	U-1983			
	>A> 9056120	Apr 11, 2023	U-1982			
	>A> 9101621	May 15, 2023	U-1985			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	>A> 9101622	May 15, 2023	U-1986			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	>A> 7189740	Apr 11, 2023	U-1982			
	>A> 7468363	Oct 07, 2023	U-1983			
	>A> 7968569	Oct 07, 2023	U-1984			
	>A> 8404717	Apr 11, 2023	U-1982			
	>A> 8530498	May 15, 2023	U-1984			
	>A> 8648095	May 15, 2023	U-1984			
	>A> 8741929	Mar 08, 2028	U-1983			
	>A> 9056120	Apr 11, 2023	U-1982			
	>A> 9101621	May 15, 2023	U-1985			
	>A> 9101622	May 15, 2023	U-1986			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	>A> 7189740	Apr 11, 2023	U-1982			
	>A> 7468363	Oct 07, 2023	U-1983			
	>A> 7968569	Oct 07, 2023	U-1984			
	>A> 8404717	Apr 11, 2023	U-1982			
	>A> 8530498	May 15, 2023	U-1984			
	>A> 8648095	May 15, 2023	U-1984			
	>A> 8741929	Mar 08, 2028	U-1983			
	>A> 9056120	Apr 11, 2023	U-1982			
	>A> 9101621	May 15, 2023	U-1985			
	>A> 9101622	May 15, 2023	U-1986			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	>A> 7189740	Apr 11, 2023	U-1982			
	>A> 7468363	Oct 07, 2023	U-1983			
	>A> 7968569	Oct 07, 2023	U-1984			
	>A> 8404717	Apr 11, 2023	U-1982			
	>A> 8530498	May 15, 2023	U-1984			
	>A> 8648095	May 15, 2023	U-1984			
	>A> 8741929	Mar 08, 2028	U-1983			
	>A> 9056120	Apr 11, 2023	U-1982			
	>A> 9101621	May 15, 2023	U-1985			
	>A> 9101622	May 15, 2023	U-1986			
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	>A> 10183012	Nov 26, 2028	U-2311			
<u>LEVODOPA - INBRIJA</u>						
N 209184 001	6514482	Sep 19, 2020	DP U-2484		NP	Dec 21, 2021
	6613308	Sep 19, 2020	U-2484			
	6858199	Nov 04, 2021	U-2485			
	6921528	Jun 19, 2020	U-2485			
	6979437	Sep 19, 2020	U-2484			
	7146978	Apr 16, 2021	U-2486			
	7182961	Feb 22, 2024	DP			
	7384649	Nov 20, 2022	DP			
	7556798	Nov 04, 2021	U-2485			
	8404276	Mar 19, 2023	U-2484			
	8545878	Nov 16, 2032	DP			
	8586093	Mar 19, 2023	U-2484			
	8628754	Jun 19, 2020	U-2485			
	8685442	Nov 16, 2032	DP			
	8945612	Nov 16, 2032	DP			
	9155699	Mar 19, 2023	DP			
	9393210	Nov 16, 2032	DP			
	RE43711	Feb 03, 2029	U-2484			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	>A> 8802628	Oct 30, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	>A> 8802628	Oct 30, 2031	DP			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	>A> 7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219 001					>A> NS	Feb 22, 2022
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	>A> 10058511	May 03, 2033	DP U-2492			
	>A> 9056057	May 03, 2033	DP U-2491			
	>A> 9393213	May 03, 2033	DP			
	>A> 9532955	May 03, 2033	U-2491			
	>A> 9737491	May 03, 2033	U-2492			
	>A> 9827191	May 03, 2033	DP U-2493			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	>A> 10172874	Aug 08, 2031	DP			
	>A> 10183034	Aug 08, 2031	U-2490			
<u>METFORMIN HYDROCHLORIDE - RIOMET</u>						
N 021591 001	6890957	Aug 07, 2021	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	10182995	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	10182995	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	10182995	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10182995	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	10182995	Mar 23, 2032	DP			
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	10195214	Jun 19, 2037	U-1643			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCYCLINE HYDROCHLORIDE</u>						
A 091424 002					>A> PC	Aug 21, 2019
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8143241	Aug 12, 2027	U-2101		>A> ODE-226	Dec 19, 2025
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8912187	Mar 12, 2024	U-2483			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8143241	Aug 12, 2027	U-2101		>A> ODE-226	Dec 19, 2025
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777			
	10183020	Jan 02, 2035	DP U-2289			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777			
	10183020	Jan 02, 2035	DP U-2289			
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	6245819	Jul 21, 2025	U-1370		>A> I-793	Jan 25, 2022
	6245819	Jul 21, 2025	U-905			
	8236861	Aug 11, 2026	U-1369			
	8236861	Aug 11, 2026	U-1370			
	8236861	Aug 11, 2026	U-905			
	8470890	Feb 13, 2024	U-1369			
	8470890	Feb 13, 2024	U-1370			
	8470890	Feb 13, 2024	U-905			
	8772353	Feb 13, 2024	U-1369			
	8772353	Feb 13, 2024	U-1370			
	8772353	Feb 13, 2024	U-905			
	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
	9241915	Feb 13, 2024	U-905			
	9855224	Feb 13, 2024	U-1369			
	9855224	Feb 13, 2024	U-1370			
	9855224	Feb 13, 2024	U-905			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	10188644	Sep 02, 2036	DP U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	10188644	Sep 02, 2036	DP U-1556			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	>A> 10188637	Mar 28, 2037	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002	>A> 10188637	Mar 28, 2037	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	>A> 10188637	Mar 28, 2037	DP			
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410 001	>A> 8987262	Oct 16, 2028	U-1988			
<u>PYRIDOSTIGMINE BROMIDE - PYRIDOSTIGMINE BROMIDE</u>						
A 211694 001					>A> CGT	Sep 04, 2019
<u>RANOLAZINE - RANOLAZINE</u>						
A 201046 001					>A> PC	May 27, 2019
<u>RANOLAZINE - RANOLAZINE</u>						
A 201046 002					>A> PC	May 27, 2019
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 001	9913860	Oct 22, 2033	DS U-2312			
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 002	9913860	Oct 22, 2033	DS U-2312			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	7762994	May 23, 2024	DP			
	>A> 8579869	Jun 30, 2023	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	7762994	May 23, 2024	DP			
	>A> 8579869	Jun 30, 2023	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	7762994	May 23, 2024	DP			
	>A> 8579869	Jun 30, 2023	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 011	7762994	May 23, 2024	DP			
	>A> 8579869	Jun 30, 2023	DP			
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108 001	>A> 10206895	Apr 01, 2034	DP U-2096			
	>A> 10206895	Apr 01, 2034	DP U-2494			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUMATRIPTAN - TOSYMRA</u>						
N 210884 001	>A> 8268791	May 09, 2026	DP			
	>A> 8440631	May 09, 2026	DP U-1719			
	>A> 9211282	Jul 19, 2031	DP U-1719			
	>A> 9283280	Jul 01, 2025	DP			
	>A> 9610280	Jun 16, 2030	DP U-1719			
	>A> 9974770	Jun 16, 2030	DP U-1719			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 001	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 002	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 003	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 004	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>TACROLIMUS - ENVARUS XR</u>						
N 206406 001	>A> 10166190	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUS XR</u>						
N 206406 002	>A> 10166190	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUS XR</u>						
N 206406 003	>A> 10166190	May 30, 2028	DP			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 001	>A> 10189837	Oct 20, 2031	DS DP			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 002	>A> 10189837	Oct 20, 2031	DS DP			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	>A> 5789379	Apr 14, 2020	DS DP U-1320		>A> ODE-37	Dec 21, 2019
	>A> 5789379*PED	Oct 14, 2020			>A> PED	Jun 21, 2020
	>A> 7056886	Sep 18, 2022	DP U-1320			
	>A> 7056886*PED	Mar 18, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	>A> 7847061	Nov 01, 2025	U-1320			
	>A> 7847061*PED	May 01, 2026				
	>A> 9060992	Nov 01, 2025	U-1320			
	>A> 9060992*PED	May 01, 2026				
	>A> 9539310	Nov 01, 2025	U-1320			
	>A> 9539310*PED	May 01, 2026				
	>A> 9545434	Nov 01, 2025	U-1320			
	>A> 9545434*PED	May 01, 2026				
	>A> 9545435	Nov 01, 2025	U-1320			
	>A> 9545435*PED	May 01, 2026				
	>A> 9555079	Nov 01, 2025	U-1320			
	>A> 9555079*PED	May 01, 2026				
	>A> 9572867	Nov 01, 2025	U-1320			
	>A> 9572867*PED	May 01, 2026				
	>A> 9592273	Nov 01, 2025	U-1320			
	>A> 9592273*PED	May 01, 2026				
	>A> 9592274	Nov 01, 2025	U-1320			
	>A> 9592274*PED	May 01, 2026				
	>A> 9968655	Nov 01, 2025	U-2308			
	>A> 9968655*PED	May 01, 2026				
	>A> 9968656	Nov 01, 2025	U-2308			
	>A> 9968656*PED	May 01, 2026				
	>A> 9968658	Nov 01, 2025	U-1320			
	>A> 9968658*PED	May 01, 2026				
	>A> 9974835	Nov 01, 2025	U-1320			
	>A> 9974835*PED	May 01, 2026				
	>A> 9974837	Nov 01, 2025	U-1320			
	>A> 9974837*PED	May 01, 2026				
	>A> 9981014	Nov 01, 2025	U-1320			
	>A> 9981014*PED	May 01, 2026				
	>A> 9981016	Nov 01, 2025	U-1320			
	>A> 9981016*PED	May 01, 2026				
	>A> 9987334	Nov 01, 2025	U-1320			
	>A> 9987334*PED	May 01, 2026				
	>A> 9987335	Nov 01, 2025	U-1320			
	>A> 9987335*PED	May 01, 2026				
	>A> 9993528	Nov 01, 2025	U-1320			
	>A> 9993528*PED	May 01, 2026				
<u>TRICLABENDAZOLE - EGATEN</u>						
N 208711 001				>A> NCE		Feb 13, 2024
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 022437 001	10166181	Feb 10, 2029	DP			
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956 001	10166181	Feb 10, 2029	DP			
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001	6258795	Jul 10, 2023	DP			
<u>URIDINE TRIACETATE - XURIDEN</u>						
N 208169 001	6258795	Jul 10, 2023	DP			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 001				>A> M-237		Feb 22, 2022
				>A> PED		Aug 22, 2022
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 002				>A> M-237		Feb 22, 2022
				>A> PED		Aug 22, 2022

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 39th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm